UNIVERSIDADE ESTADUALPAULISTA

“JULIO DE MESQUITA FILHO”

FACULDADE DE MEDICINA VETERINÁRIA

Campus de Araçatuba

SIDNEI FERRO COSTA

ESTIMULAÇÃO COMBINADA DE IL-12 E IL-15 PROMOVE A RESPOSTA IMUNE CELULAR EM CÃES COM LEISHMANIOSE VIA IFN-y

Araçatuba

2019

SIDNEI FERRO COSTA

ESTIMULAÇÃO COMBINADA DE IL-12 E IL-15 PROMOVE A RESPOSTA IMUNE CELULAR EM CÃES COM LEISHMANIOSE VIA IFN-y

Dissertação apresentada à Faculdade de Medicina Veterinária de Araçatuba da Universidade Estadual Paulista "Júlio de Mesquita Filho" – UNESP, como parte dos requisitos para a obtenção do título de Mestre em Ciência Animal (Área de Medicina Veterinária Preventiva e Produção Animal).

Orientadora: Prof.ª Ass. Valéria Marçal Felix de Lima

Araçatuba

2019

C837e

Costa, Sidnei Ferro
Estimulação combinada de IL-12 e IL-15 promove a resposta imune celular em cães com leishmaniose via IFN-y / Sidnei Ferro Costa. -- Araçatuba, 2019
70 p.

Dissertação (mestrado) - Universidade Estadual Paulista (Unesp), Faculdade de Medicina Veterinária, Araçatuba
Orientadora: Valéria Marçal Felix de Lima

1. Leishmaniose. 2. Cães. 3. Imunologia. 4. Interleucina-12. 5. Interleucina-15. I. Título.

Sistema de geração automática de fichas catalográficas da Unesp. Biblioteca da Faculdade de Medicina Veterinária, Araçatuba. Dados fornecidos pelo autor(a).

Essa ficha não pode ser modificada.

UNIVERSIDADE ESTADUAL PAULISTA

Câmpus de Araçatuba

CERTIFICADO DE APROVAÇÃO

Título: ESTIMULAÇÃO COMBINADA DE IL-12 E IL-15 PROMOVE A RESPOSTA IMUNE CELULAR EM CÃES COM LEISHMANIOSE VIA IFN-γ

AUTOR: SIDNEI FERRO COSTA
ORIENTADORA: VALERIA MARÇAL FELIX DE LIMA

Aprovado como parte das exigências para obtenção do Título de Mestre em CIÊNCIA ANIMAL, área: Medicina Veterinária Preventiva e Produção Animal pela Comissão Examinadora:

Profa. Dra. VALERIA MARÇAL FELIX DE LIMA
Departamento de Clínica, Cirurgia e Reprodução Animal / Faculdade de Medicina Veterinária - Câmpus de Araçatuba/Unesp

Pesquisadora FLÁVIA LOMBARDI LOPES
Departamento de Apoio, Produção e Saúde Animal / Faculdade de Medicina Veterinária - Câmpus de Araçatuba/Unesp

Profa. Dra. SANDRA HELENA PENHA DE OLIVEIRA
Departamento de Ciências Básicas / Faculdade de Odontologia - Câmpus de Araçatuba/Unesp

Araçatuba, 20 de maio de 2019.

AGRADECIMENTOS

Agradeço a minha família e aos meus amigos, que sempre me apoiaram principalmente nos momentos difíceis, somente vocês sabem a importância e o significado desse trabalho na minha vida. Amo vocês!

A minha orientadora Valéria Marçal Felix de Lima que me propiciou essa oportunidade, sempre muito receptiva e atenciosa, me ouvindo nas horas de dúvidas, me ensinando sempre a melhor maneira de conduzir os experimentos, a escrever da melhor forma. Tenha certeza que encerro esse ciclo sendo uma pessoa muito melhor do que quando comecei. Muito obrigado por tudo!

As colegas do Laboratório de Imunologia Marilene Oliveira dos Santos Maciel, Larissa Martins Melo, Gabriela Lovizutto Venturin, Jaqueline Poleto Bragato, Gabriela Torres Rebech, sempre companheiras, inteligentes e dispostas a ajudar. Esse trabalho não é somente meu, mas nosso.

A técnica Flavia Mari Yamamoto por toda ajuda com os experimentos, sua humildade, disciplina e dedicação ao trabalho são exemplos que vou levar comigo para o resto da vida.

A minha banca de qualificação, Profª Flavia Lombardi Lopes e Profª Juliana Regina Peiró que me servem de exemplo profissional pela dedicação e comprometimento, obrigado pelas considerações dadas ao meu trabalho.

Agradeço a todos os professores que de alguma forma me ajudaram e me deram apoio ao longo dessa caminhada. Obrigado!

Ao programa de Pós-graduação em Ciência Animal e a Faculdade de Medicina Veterinária Campus de Araçatuba pela oportunidade, por toda a infraestrutura oferecida e por ser tão bem recebido por todos.

O apoio da Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) processo nº 2017/10906-8 que financiou a pesquisa que deu origem ao artigo científico.

E a CAPES por financiar o discente por um período.

COSTA, S.F. et al. **Estimulação combinada de IL-12 e IL-15 promove a resposta imune celular em cães com leishmaniose via IFN-y.** 2019. 70 f. Dissertação (Mestrado) - Faculdade de Medicina Veterinária, Universidade Estadual Paulista, Araçatuba, 2019.

RESUMO

A Leishmaniose Visceral (LV) é causada nas Américas, pelo protozoário intracelular obrigatório *Leishmania infantum* e os cães domésticos são os principais reservatórios urbanos do parasita e em áreas endêmicas, o aumento da LV em humanos tem sido associado ao aumento da infecção canina. Os atuais medicamentos disponíveis para a Leishmaniose Canina (CanL) não são completamente eficientes e meses após o tratamento a maioria dos cães apresentam recidiva, indicando a necessidade de buscar formas alternativas de tratamento. Na CanL, cães desenvolvem uma resposta imune celular (Th1) ineficiente para combater o parasita e a estimulação das vias de citocinas em células de defesa com proteínas recombinantes, tem o potencial de se tornar parte de métodos imunoterapêuticos eficazes. Neste estudo, as citocinas recombinantes caninas (IL-12, IL-2, IL-15 e IL-7) e o receptor solúvel de IL-10R1 (sIL-10R1), com atividade antagonista, foram avaliadas pela primeira vez em combinações (IL-12/IL-2, IL-12/IL-15, IL-12/sIL-10R1, IL-15/IL-7) ou isoladamente (sIL-10R1) quanto à capacidade imunomodulatória em células mononucleares do sangue periférico (sigla em inglês PBMC) de cães com leishmaniose. Todas as combinações de proteínas recombinantes testadas mostraram melhorar a resposta linfoproliferativa. Além disso, as combinações de IL-12/IL-2 e IL-12/IL-15 promoveram a diminuição na expressão da proteína "Programed Cell Death 1" (PD-1) nos linfócitos. Estas mesmas combinações de citocinas e IL-12/sIL-10R1 induziram a produção de IFN-y nas PBMCs. Além disso, a combinação de IL-12/IL-15 aumentou expressão de T-bet nos linfócitos. Esses achados estimulam o uso de IL-12 e IL-15 em futuros estudos *in vivo* com o objetivo de obter a polarização da resposta imune celular em cães com leishmaniose, o que pode contribuir para o desenvolvimento de um tratamento efetivo contra a CanL.

Palavras-chave: Leishmaniose. Cães. Imunologia. Interleucina-12. Interleucina-15

COSTA, S.F. et al. **Combined stimulation by IL-12 and IL-15 promotes cellular immune response in dogs with visceral leishmaniasis via IFN-y.** 2019. 70 f. Dissertação (Mestrado) - Faculdade de Medicina Veterinária, Universidade Estadual Paulista, Araçatuba, 2019.

ABSTRACT

Visceral Leishmaniasis (LV) is caused in the Americas by the obligate intracellular protozoan *Leishmania infantum* and domestic dogs are the major urban reservoirs of the parasite and in endemic areas, and increase LV in humans has been associated with increased canine infection. The current medications available for Canine Leishmaniasis (CanL) are not completely effective and months after treatment most dogs present with relapse, indicating the necessity to looking for alternative forms of treatment. In CanL, dogs develop an ineffective cellular immune response (Th1) to combat the parasite. Then, the stimulation of cytokine pathways in defense cells with recombinant proteins, has the potential to become part of effective immunotherapeutic methods. In this study, the canine recombinant cytokines (IL-12, IL-2, IL-15 and IL-7) and the soluble receptor of IL-10R1 (sIL-10R1) with antagonistic activity, were evaluated for the first time in combinations IL-12/IL-2, IL-12/IL-15, IL-12/sIL-10R1, IL-15/IL-7) or alone (sIL-10R1) for their immunomodulatory capacity in peripheral blood mononuclear cells (PBMC) from dogs with leishmaniasis. All combinations of recombinant proteins tested were shown to improve lymphoproliferative response. Further, combinations of IL-12/IL-2 and IL-12/IL-15 promoted decrease in programmed cell death protein 1 (PD-1) expression in lymphocytes. These same combinations of cytokines and IL-12/casIL-10R1 induced IFN-y production in PBMC. Furthermore, the combination of IL-12/IL-15 led to an increased T-bet expression . These findings encourage the use of IL-12 and IL-15 in future in vivo studies aiming to get polarization of cellular immune response in dogs with leishmaniasis, that may contribute to development of an effective treatment against CanL.

Keywords: Leishmaniasis. Dogs. Immunology. Interleukin-12. Interleukin-15.

SUMÁRIO

1 INTRODUÇÃO GERAL 9
1.1 Aspectos clínicos e epidemiológicos da Leishmaniose Visceral 9
1.2 Caracterização da Leishmaniose Canina 10
1.3 Resposta Imunológica na Leishmaniose Canina..11
1.4 Estimulação e bloqueio da sinalização de citocinas com proteínas recombinantes na Leishmaniose 13
2 CAPÍTULO 1 - COMBINED STIMULATION BY IL-12 AND IL-15 PROMOTES CELLULAR IMMUNE RESPONSE IN DOGS WTH LEISHMANIASIS VIA IFN-y......16
2.1 Abstract 17
2.2 Author summary 17
2.3 Introduction...18
2.4 Methods..20
2.4.1 Screening of animals and sample collection...20
2.4.2 Isolation of peripheral blood mononuclear cells..21
2.4.3 Production of canine recombinant cytokines and soluble IL-10R1 receptor 21
2.4.4 Lymphoproliferation assay...22
2.4.5 Flow cytometric analysis for labeling PD-1, T-bet and GATA3 in PBMC 23
2.4.6 Statistical analysis 24
2.5 Results 24
2.5.1 Description of clinical and laboratory findings of the animals used in the study24
2.5.2 Combinations of canine recombinant cytokines and/or soluble IL-10R1 receptor induce lymphoproliferation in naturally infected sick dogs 25
2.5.3 Combination of IL-12/IL-2 or IL-12/IL-15 promotes decrease in lymphocyte PD-1 expression 26
2.5.4 Combination of IL-12/IL-15 induces an increase in T-bet without altering GATA3 expression 27
2.5.5 Combinations of IL-12/IL-2, IL-12/IL15 or IL-12/sIL-10R1 provoke an increase in IFN-γ without altering IL-10 production..29
2.6 Discussion...30
2.7 Acknowledgment 34
REFERENCE 34
2.8 Support information...45

REFERÊNCIAS DA INTRODUÇÃO GERAL..52
ANEXO..64

1 INTRODUÇÃO GERAL

1.1 Aspectos clínicos e epidemiológicos da Leishmaniose Visceral

Leishmanioses são doenças causadas por protozoários do gênero *Leishmania,* da ordem *Kinetoplastida* e família *Trypanosomatidae* [1]. O gênero *Leishmania* compreende um grupo importante de parasitas intracelulares obrigatórios que são os agentes causadores das leishmanioses. As formas clínicas da doença no homem se apresentam em três diferentes formas dependendo da espécie de *Leishmania* e da resposta imune do hospedeiro: Leishmaniose Cutânea (LC), é a forma mais ocorrente e caracterizada por lesões ulcerativas na pele; Leishmaniose Mucocutânea, caracteriza pela destruição parcial ou total das mucosas e Leishmaniose Visceral (LV) conhecida também como Kalazar, caracterizada por episódios irregulares de febre, perda substancial de peso, inchaço do baço, fígado e anemia [2].

A LV é a forma clínica mais grave das leishmanioses com uma letalidade de mais de 95% em pacientes que não são submetidos a nenhum tipo de tratamento [3] sendo uma das doenças mais negligenciadas do mundo e classificada entre as seis doenças tropicais mais importantes [4]. As espécies de *Leishmania* que causam a doença visceral pertencem ao subgênero *Leishmania* e incluem *Leishmania (L.) donovani* e *L. infantum* na Europa e *L. chagasi* ou *L. infantum* nas Américas.

A ocorrência da LV é amplamente distribuída no mundo, principalmente em regiões tropicais e subtropicais com aproximadamente 300.000 novas infeções a cada ano e estimativa de 20.000 a 50.000 mortes anualmente em decorrência da doença [4]. O Brasil é uma região endêmica para LV com a maioria dos casos concentrados na região Nordeste (44%) seguida da região Sudeste (22%) e em 2017 foram 4.013 registros da doença com 327 óbitos [5]. Dos casos de LV registrados no Brasil no ano de 2017, 31 foram na região noroeste do estado de São Paulo, com 4 mortes [6]. No estado de São Paulo, a doença foi notificada pela primeira vez no município de Araçatuba no ano de 1999, quando foi confirmado o primeiro caso canino autóctone no município [7] e até o ano de 2013 foram 2.324 casos registrados no estado com mais de 200 óbitos em humanos [8].

A transmissão entre hospedeiros vertebrados no Brasil é feita pela picada da fêmea do flebotomíneo hematófago *Lutzomyia longipalpis* [9], porém outras

espécies já foram identificadas como vetores da doença [10]. Mesmo com a dispersão dos flebotomíneos para quase todas as regiões do Brasil, a ausência do vetor em áreas onde existem casos de LV sugere a existência de outros modos de transmissão da enfermidade [11]. Pulgas [12] e carrapatos [12,13] também já foram incriminados como possíveis transmissores de *L. Infantum*. Já foi descrita também a ocorrência de transmissão venérea [14], vertical [15–17] e por transfusão sanguínea [18].

Os cães domésticos (*Canis familiaris*) são os principais reservatórios de *L. infantum* em áreas urbanas [19] e em áreas endêmicas há uma correlação entre a prevalência de cães soropositivos e o número de casos da doença em humanos [20,21]. Essa relação cães soropositivos versus LV humana acontece devido á proximidade dos cães com os humanos; pelos cães infectados possuírem alto parasitismo na pele, principalmente em regiões ulceradas, o que favorece o contágio de novos vetores e facilita a transmissão da doença [22]; pela alta prevalência de cães infectados em áreas endêmicas e poucos apresentarem a forma sintomática da doença [23] o que dificulta o diagnóstico e consequentemente o controle do parasita no cão infectado [24]. Portanto, os cães são importantes na manutenção do ciclo epidemiológico da LV e o controle da doença no homem não acontece sem um controle efetivo da doença no cão [25].

1.2 Caracterização da Leishmaniose Canina

Nos cães, a infecção por *L. infantum*, tem início após a inoculação de formas promastigotas metacíclicas na pele durante o repasto sanguíneo da fêmea do flebotomíneo. Embora não existam evidências diretas de todas as etapas do processo de instalação da doença no cão, no homem ou mesmo em modelo murino, o cenário geral parece ser o descrito a seguir. As promastigotas de *L. infantum* são fagocitadas por células fagocíticas residentes ou recrutadas como macrófagos e neutrófilos [26]. No interior das células fagocíticas, as promastigotas (que exibem flagelo aparente) se aderem aos fagossomos e transformam-se em formas amastigotas (que possuem flagelo restrito à bolsa flagelar) [27]. Neutrófilos contendo leishmanias podem sofrer apoptose e serem fagocitados por macrófagos, transferindo assim a sua carga parasitária. Os macrófagos produzem óxido nítrico (NO) para eliminação do parasita [28], no entanto, nesse primeiro momento a

ativação de mecanismos leishmanicidas dos macrófagos não é suficiente para evitar a propagação do parasita [29].

Sem uma contenção apropriada, as amastigotas se multiplicam por divisão binária dentro dos macrófagos e são transportadas para o linfonodo de drenagem e a partir daí, no interior dos macrófagos, disseminam-se para diversos órgãos ricos em células do sistema fagocítico mononuclear [30] como o baço, fígado e a medula óssea [26]. Nesses órgãos, as leishmanias continuam a proliferar no interior de macrófagos até ocasionar a ruptura da célula e dessa forma infectar outros macrófagos [31] induzindo uma inflamação crônica, frequentemente granulomatosa, que promove alterações funcionais e estruturais [32,33] e consequentemente, causar a doença.

A Leishmaniose Canina (CanL) é manifestada por lesões e sintomas característicos. Os sinais clínicos mais frequentes da CanL são lesões na pele, linfoadenopatia, onicogrifose, perda de peso, caquexia, febre e doença renal [34]. Além da sintomatologia clássica, o parasita pode eventualmente causar danos ao sistema reprodutor masculino [35] podendo inclusive ser detectado no sêmen [36]. Alterações laboratoriais também são encontradas nos cães doentes, dentre elas anemia não regenerativa, hipoalbuminemia, hiperglobulinemia, trombocitopenia, proteinúria, azotemia renal e aumento de enzimas hepáticas [34]. O número e a intensidade dos sinais clínicos são determinados por um conjunto de fatores que envolvem a cepa do parasita, a genética e principalmente o estado imunológico do hospedeiro [24]. Desta forma, alguns cães são capazes de controlar a infecção por um período de tempo sem o aparecimento de sinais [23,37], e às vezes pode até evoluir para cura espontânea, entretanto, alguns cães apresentam evolução aguda ou curso progressivo que leva à morte, se o manejo e a terapia adequadas não forem adotadas [24].

1.3 Resposta Imunológica na Leishmaniose Canina

A resposta imunológica desenvolvida pelo cão durante a CanL é complexa e determinante na resistência ou susceptibilidade a doença [28,38]. A imunidade inata é a primeira linha de defesa contra *L infantum*. A pele age como primeira barreira de proteção por meio da ativação das vias clássicas e alternativas do sistema complemento [28], no entanto a saliva do flebotomíneo pode inibir a ação

do complemento e consequentemente induzir a falha da resposta imune já no momento da inoculação [39]. Moléculas dos parasitas sobreviventes à ação do complemento são detectadas por receptores da imunidade inata presentes em células dendríticas, células natural killer e macrófagos [40]. Entre esses receptores imunes inatos estão os receptores Toll-like (TLRs), que utilizam proteínas adaptadoras como o MyD88 para desencadear a produção de citocinas pró-inflamatórias, tais como TNF-α, IFN-γ e IL-12, bem como moléculas coestimuladoras que ativam momentaneamente mecanismos leishmanicidas dos macrófagos infectados e induzem a resposta imune adaptativa [41,42].

Os mecanismos inatos desempenham um papel importante nas defesas anti-*Leishmania* [43], no entanto a montagem eficiente de uma resposta imune adaptativa é indispensável para o controle da infecção. A resposta imune adaptativa envolvida no reconhecimento e controle da infeções por patógenos intracelulares, incluindo a infecção causada por *L. infantum*, é a resposta imune celular ou Th1 [44]. Durante essa resposta, células apresentadoras de antígeno, incluindo células dendríticas, capturam leishmanias ou fragmentos delas na pele e migram para região T do linfonodo de drenagem [26,45]. As células dendríticas que amadurecem em condições de estimulação intensa desenvolvem a capacidade de expressar moléculas co-estimulatórias e produzir IL-12 [46]. No linfonodo, após processamento de antígenos do protozoário, células dendríticas que expressam peptídeos da leishmania acoplados a moléculas do complexo principal de histocompatibilidade (classe I e classe II), moléculas co-estimulatórias membros da família B7 como (por exemplo, CD80 e CD86) [47], produzem IL-12 [48] e são capazes de estimular a proliferação e a diferenciação de linfócitos T naïve em linfócitos T efetores (T CD4+ e T CD8+) Th1. Com a diferenciação, as células T CD4+ Th1 produzem INF-γ e TNF-α nos tecidos afetados pela infecção e essas citocinas ativam mecanismos leishmanicidas, incluindo a produção de óxido nítrico e espécies reativas de oxigênio (H_2O_2 e íon superóxido) nos macrófagos infectados pelo protozoário [48–50] e, dessa maneira, eliminam o parasita.

Cães doentes, susceptíveis a CanL e sintomáticos, falham em montar uma resposta imune celular Th1 eficiente contra o parasita concomitante ao aumento da resposta imune humoral ou Th2, que resulta na ativação das células B, produção exacerbada de anticorpos [51,52] e uma incontrolável multiplicação do parasita [53]. O aumento da carga parasitária e a supressão da imunidade celular na

CanL, podem ser acompanhados pelo aumento da expressão da citocina IL-10 [54–57]. Essa citocina é produzida por várias células, incluindo linfócitos T regulatórios (Treg), linfócitos Th2 [58] e células B [59], sendo considerada um regulador da atividade Th1 que mantém o equilíbrio entre as respostas Th1 e Th2 e inibe a atividade microbicida de macrófagos infectados [38,60].

A falha do cão doente em montar uma resposta adaptativa eficiente contra o parasita pode ser também, pelo menos em parte, associada ao aumento da expressão da molécula de co-estimulação negativa PD-1 (programed cell death 1). O PD-1 também conhecido como CD279 é um membro da família B7-CD28 expresso por células imunológicas [61]. Quando associado aos seus ligantes PD-L1 ou PD-L2, PD-1 induz a desativação e apoptose de células T [62]. O aumento da expressão de PD-1 em células T CD4+ de cães infectados com *L. infantum* e sintomáticos, quando submetidos ao estímulo antígeno específico para avaliação da proliferação celular, resultou em redução dessa resposta comparada a animais assintomáticos [63]. Em linfócitos T, B e macrófagos, o aumento da expressão de PD-1 e seus ligantes foi associado à apoptose dos linfócitos T em células esplênicas e mononucleares do sangue periférico de cães doentes [64] e a alta expressão de PD-1 também alterou a produção de citocinas relacionadas com a progressão da CanL [65].

1.4 Estimulação e bloqueio da sinalização de citocinas com proteínas recombinantes na Leishmaniose

A resistência ou susceptibilidade a infecção por *L.infantum* depende muito do tipo de resposta imune montada (Th1 versuus Th2) e a estimulação da sinalização de citocinas que estimula a resposta Th1 (IL-2, IL-12, IL-15) e o bloqueio da sinalização de citocinas que estimulam a resposta Th2 (IL-10) tem sido utilizados em estudos *in vitro* na CanL e na LV humana com o objetivo de desenvolver métodos imunoterápicos para o tratamento da doença [55,66–70].

A IL-2 é uma citocina produzida por várias células do sistema imunológico quando ativado, incluindo células TCD4+, células natural killer (NK), células dendríticas (DCs) e mastócitos [71]. A IL-2 é o principal fator estimulador de células T, sendo um fator de crescimento e ativação para todas as subpopulações de linfócitos T, induzindo ciclo celular para células T não ativadas e a expansão clonal

de células T ativadas [72]. Em pacientes humanos infectados com *L. infantum*, a adição de antígeno solúvel de *Leishmania* (AtgS) combinado com IL-2 recombinante humano (rhuIL-2) e IFN-y recombinante humano (rhuIFN-y) em cultura de PBMC restaurou a resposta linfoproliferativa [73].

A IL-15 é uma citocina sintetizada por diversos tipos celulares, incluindo monócitos/macrófagos, células dendríticas, estroma da medula óssea e células epiteliais do timo, e que exerce um vasto espectro de atividades biológicas, incluindo proliferação e ativação de células NK [74] e proliferação e sobrevivência de linfócitos T de memória [75,76]. A IL-15 é uma das citocinas que induzem as células NK a produzir INF-γ [77] e tem atividade biológica similar a IL-2 [78], aumentando tanto respostas Th1 quanto Th2. Contudo, foi demonstrado que esta citocina pode mudar o equilíbrio entre Th1 e Th2 para resposta Th1 [79]. A adição de IL-15 recombinante humana (rhuIL-15) em cultura de PBMC de pacientes humanos com LV ativa diminuiu a citocina Th2 IL-4 e aumentou a citocina Th1 IL-12 [80].

A IL-12 é uma citocina heterodimérica produzida por células inflamatórias (monócitos, macrófagos, neutrófilos e células dendríticas) em resposta a patógenos intracelulares. IL-12 induz a produção de INF-γ pelas células NK e células T e é importante na indução e manutenção da resposta Th1 [81]. A adição de IL-12 recombinante humana (rhuIL-12) e o bloqueio de IL-10 e IL-4 com anticorpos monoclonais (mAb) em cultura de PBMC de pacientes humanos com LV, restauraram a resposta linfoproliferativa e a produção de IFN-y. Na CanL, a adição de IL-12 recombinante canina (rcaIL-12) em cultura de PBMC de cães naturalmente infectados por *L. infantum* promoveu aumento da expressão de RNA e dos níveis de IFN-y no sobrenadante da cultura [70,82] e melhorou a resposta linfoproliferativa após estimulação com AtgS [70].

A IL-7 é uma citocina produzida por células do estroma da medula óssea e do timo, fibroblastos reticulares em regiões T dos linfonodos e induz diversas atividades biológicas, incluindo reconstituição linfóide e a proliferação e sobrevivência de células T de memória [83]. Não há estudos sobre o papel da IL-7 em infecções por *Leishmania spp.* em humanos ou em cães e seu papel na polarização das células T não foi definido. Entretanto, a IL-7 murina, especialmente quando combinada com IFN-y, demonstrou promover forte efeito leishmanicida em macrófagos de camundongos infectados com *L. major* [84].

Embora na leishmaniose visceral humana e canina, a estimulação de uma única citocina já tenha demonstrado efeitos benéficos, tem sido observado que quando as citocinas são utilizadas em combinações de duas ou mais, podem promover efeitos biológicos mais desejáveis. Em cães, estudo *in vitro* mostrou que rcaIL-12 sozinha foi capaz de induzir a produção de baixas quantidades de IFN-γ por linfócitos de cães infectados com *L. infantum* [70], entretanto, em cães saudáveis, a combinação rcaIL-12 e IL-2 recombinantes canino (rcaIL-2) induziu maior produção de IFN-γ comparado ao efeito isolado dessas citocinas [85]. Em pacientes humanos infectados por *L. infantum*, rhuIL-15 induziu resposta Th1, mas não alterou a produção de IFN-γ *in vitro* [80]. No entanto a IL-15 em sinergia com IL-12 ativou a produção de IFN-γ e induziu a resposta Th1 em infecções por parasitas intracelulares [86]. Portanto, é possível que a estimulação combinada da sinalização de citocinas tenha melhor efeito imunomodulatório na CanL do que a estimulação da sinalização de uma única citocina.

Os atuais tratamentos disponíveis para a CanL promovem redução da carga parasitária, cura clínica, diminuem a infecciosidade, melhoram a qualidade e aumentam a expectativa de vida [24,87,88]. Entretanto, ao final da terapia, a maioria dos cães tratados tem recidiva tornando-se novamente potenciais fontes de transmissão de *L. infantum* para cães saudáveis e humanos [24,88]. Assim, visando o desenvolvimento de métodos imunoterápicos para CanL, citocinas recombinantes caninas (IL-12, IL-2, IL-15 e IL-7) e o receptor solúvel de IL-10R1 (sIL-10R1), com atividade antagonista, foram avaliados pela primeira vez em combinações (IL-12/IL-2, IL-12/IL-15, IL-12/casIL-10R1, IL-15/IL-7) ou isoladamente (sIL-10R1) quanto à capacidade imunomoduladora em PBMC de cães com leishmaniose.

2 CAPÍTULO 1 - COMBINED STIMULATION BY IL-12 AND IL-15 PROMOTES CELLULAR IMMUNE RESPONSE IN DOGS WITH LEISHMANIASIS VIA IFN-Y

Sidnei Ferro Costa[a], Vinícius Oliveira Gomes[a], Marilene Oliveira dos Santos Maciel[a], Larissa Martins Melo[a], Gabriela Lovizutto Venturin[a], Jaqueline Poleto Bragato[a], Gabriela Torres Rebech[a], Catiule de Oliveira Santos[b], Bárbara Maria Nascimento de Oliveira[b], Geraldo Gileno de Sá Oliveira[b¶], Valéria Marçal Felix de Lima[a¶*]

[a]Department of Clinics, Surgery and Animal Reproduction, São Paulo State University (UNESP), School of Veterinary Medicine, Araçatuba

[b]Laboratório de Patologia e Bio-Intervenção LAPEM, Instituto de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz, Rua Waldemar Falcão, No. 121, Candeal, Salvador, Bahia, Brazil

[¶]These authors contributed equally to this work.

*Corresponding Author:

Department of Clinical, Surgery and Animal Reproduction, São Paulo State University (UNESP), School of Veterinary Medicine, Araçatuba

793 Clóvis Pestana St. - Jardim Dona Amélia

Zip Code: 16050-680 - São Paulo, Brazil

Phone Number: +55-18-36361422

Email: Sidnei Ferro Costa: sidnei-fcosta@hotmail.com

Valéria Marçal Felix de Lima: valeria.lima@unesp.br

PLOS Neglected Tropical Diseases – ANEXO A

2.1 Abstract

Domestic dogs are the main reservoir of *Leishmania infantum*, a causative agent of visceral leishmaniaisis (VL) in the Americas. There is an association between the number of human disease cases and rate of canine infection. Drugs currently available are not efficient to treat Canine Leishmaniasis (CanL), months after the treatment most dogs show disease relapse, therefore, development of new drugs or new therapeutic strategies should be sought. In CanL, sick dogs lack the ability mount a specific cellular immune response suitable to combat the parasite and manipulation of cytokine signaling pathway has the potential to become part of effective immunotherapeutic methods. In this study, canine recombinant cytokines (IL-12, IL-2, IL-15 and IL-7) and soluble receptor IL-10R1 (sIL-10R1), with antagonistic activity, were evaluated for the first time in combinations (IL-12/IL-2, IL-12/IL-15, IL-12/sIL-10R1, IL-15/IL-7) or isolated (sIL-10R1) for their immunomodulatory capacity in peripheral blood mononuclear cells (PBMC) from dogs with leishmaniasis. All combinations of recombinant proteins tested were shown to improve lymphoproliferative response. Further, combinations of IL-12/IL-2 and IL-12/IL-15 promoted decrease in programmed cell death protein 1 (PD-1) expression in lymphocytes. These same combinations of cytokines and IL-12/sIL-10R1 induced IFN-y production by PBMC. Furthermore, the combination of IL-12/IL-15 led to an increased T-bet expression in lymphocytes. These findings encourage the use of IL-12 and IL-15 in future *in vivo* studies aiming to get polarization of cellular immune response in dogs with leishmaniasis, which may contribute to development of an effective treatment against CanL.

2.2 Author summary

Dogs are the major reservoirs of *Leishmania infantum*, a protozoan parasite that causes a human systemic lethal disease (Visceral Leishmaniasis, VL) and dogs in the Americas. Currently, the disease is often associated with extensive skin lesions and may be named canine leishmaniasis (CanL). The containment canine infection/disease may help controlling human VL. Drugs currently available in the market are not effective in the treatment of CanL, months after the treatment most dogs develop disease relapse, even if they are taken out of the endemic area. Developing of new drugs or alternative therapeutic strategies are necessary for

proper treatment of the canine disease. Dogs that acquire the parasite may develop disease or control the infection depending on the type of immune response that is mounted. Cellular immune responses leads to infection control and prevent the development of the disease. Some proteins called cytokines, which are produced mainly by cells of the immune system, can favor the development of cellular immune responses. In this study, several recombinant cytokines and/or one cytokine blocking protein have been tested, in combinations or isolated, for their ability to promote cellular immune response in dogs with leishmaniasis. Of all combinations of recombinant protein tested, one showed to be the best to favor cellular immune responses. The findings reported here encourage the use of a combination of two recombinant cytokines (IL-12/IL-15) in future immunotherapeutic trials for CanL.

2.3 Introduction

The zoonotic form of visceral leishmaniasis (VL) is caused by the obligate intracellular protozoan *Leishmania infantum* (syn. *L. chagasi*, in the Americas). VL is the most severe form of leishmaniasis and is fatal in 95% of untreated cases [1]. VL is widely distributed worldwide, occurring mainly in tropical and subtropical regions with approximately 300.000 new infections each year and an estimated 20.000 to 50.000 deaths [2]. In Brazil, the numbers of human disease cases has increased annually and, in 2017, 4.013 cases were reported, with 327 deaths [3]. Domestic dogs are considered the main reservoir of the parasite in urban areas [4]. In endemic areas, there is a correlation between prevalence of seropositive dogs and number of human cases of VL [5–7], suggesting that controlling infection and/or disease in dogs (CanL) may contribute to effectively curbing human disease [8].

The current treatments available for CanL have leishmanicide and leshmaniostatic effects [9] and lead to reduction of parasite load, infectiousness, and disappearance of clinical signs [10,11]. However, most dogs remain infected and experience disease relapse months after treatment withdrawal, and become again a source of parasites for other healthy dogs and humans [10]. Frequent disease relapses following currently available therapy suggest that new drugs or therapeutic approaches for CanL, for example, association of existing drugs with immunostimulants, should be sought [12].

Dogs resistant to infection by *L. infantum* develop an efficient cellular immune response (Th1) with simultaneous production of IFN-γ, IL-2, and IL-12 [13–15] and activation of leishmanicidal mechanisms in infected macrophages [16,17]. In contrast, dogs that are susceptible to the infection, mount an exacerbated humoral immune response (Th2) that may be accompanied by increased production of IL-10 [18]. In addition, susceptible dogs present increased expression levels of programmed cell death 1 (PD-1) and PD-1 ligands (PD-L1 and PDL-2), which are part of an immune inhibitory signaling pathway (a inhibitory immune checkpoint), in splenic cells [19]. Such heightened expression of PD-1 and PD-1 ligands may suppress lymphoproliferation and alter the production of Th1 cytokines and contribute to development of the disease [20]. Outcome of infection, caused by *L. infantum* in humans and dogs, relies largely on the type of adaptive immune response mounted (Th1 vs Th2) and cytokines that help to shape such responses [14,15,18,21–24]. Manipulations of certain cytokine signaling pathways may favor control over the parasite in infected individuals. Interestingly, even after mounting an adaptive immune response inefficient to combat *L. infantum*, allowing for the development of the disease, subsequent treatment with antimonials or amphotericin B lead most humans to reprogram their specific immune responses [22,23], keeping the parasite replication under control, and inhibiting disease recurrence.

Peripheral blood mononuclear cells (PBMC) from human patients with VL, stimulated with soluble *leishmania* antigens (SLA) in combination with recombinant human interferon gamma (rhuIFN-γ) and interleukin-2 (rhIL-2), present restoration of lymphoproliferative response [22]. Further, stimulation of PBMC with SLA together with rhuIL-12, or blocking signaling with anti-IL-10 and/or IL-4 antibodies, results in both restoration of lymphoproliferative response and production of IFN-γ [22,23,25]. Addition of rhuIL-15 to PBMC cultured with SLA promotes a decrease of IL-4 and an increase of IL-12 production [26]. Still, in humans with VL, blockade of IL-10 signaling by anti-IL10 antibodies induces increased levels of IFN-y in splenic cells [27]. In sick dogs naturally infected with *L. infantum*, treatment of PBMC with recombinant canine IL-12 (rcaIL-12) generates an increase in IFN-y mRNA expression and protein production [21,28] and a tendency to enhance lymphoproliferative response to SLA [21]. To the best of our knowledge, attempts to evaluate activities of IL-7 in humans or dogs with visceral leishmaniasis, have not yet been carried out. Murine IL-7,

especially when combined with IFN-y, shows strong leishmanicidal effect on autologous macrophages infected with *L. major* [29].

Although interfering with a single cytokine pathway, with agonistic or antagonistic molecules, can drive responses in cells of the immune system, simultaneous intervention in two or more cytokines signaling pathways may elicit stronger responses in these cells, even in low cytokine concentration settings [30–33]. Successful attempts to modify immune responses in human or dog PBMC by the use of combination of cytokines exhibiting additive or synergistic effects have already been performed. For instance, human IL-15 combined with IL-12 promotes higher levels of IFN-γ, as compared to IL-15 or IL-12 individually, and may generate effective responses to infections caused by intracellular parasites [34]. In addition, canine IL-12 and IL-2 together stimulate efficient production of IFN-γ, whereas IL-12 or IL-2 alone fail to induce a significant increase in IFN-y levels [35,36].

In this study, recombinant canine proteins (IL-12, IL-2, IL-15 or IL-7 or soluble IL-10 receptor with antagonistic activity) were evaluated for their capacity to modulate immune responses in PBMC from dogs with leishmaniasis. These recombinant proteins were assessed in combinations or isolated for the first time. Lymphoproliferation, exhibition of PD-1 on lymphocyte surface, production of IFN-γ and IL-10, and expression of T-bet and GATA3 were evaluated in lymphocytes following treatments. Recombinant proteins tested herein, showed activities potentially capable of stimulating macrophages to control replication or destroy *L. infantum,* which could have a positive impact for the development of immunotherapeutic protocols for CanL.

2.4 Methods

2.4.1 Screening of animals and sample collection

This study was approved by the Brazilian Collegiate Board for Ethical Animal Experimentation (COBEA), and received approval from the UNESP Institutional Committee for Animal Care and Use (Universidade Estadual Paulista Júlio de Mesquita Filho, Araçatuba, School of Veterinary Medicine - FMVA/Protocol # 00765-2017).

Five healthy dogs from Araçatuba, São Paulo, with negative results for the detection of *Leishmania* DNA by real time PCR, as well as complete blood counts

and mean serum biochemistry parameters within reference ranges (Table S2 and S3 and S4), were used as negative controls. A total of ten dogs were selected from the Araçatuba Zoonosis Control Center if they showed at least three of the following clinical signs characteristic of CanL: onychogryphosis, cachexia, ear-tip injuries, periocular lesions, alopecia, skin lesions or lymphadenopathy (Table S1).

Blood samples from both groups, healthy controls and diseased dogs, were collected in either tubes without EDTA, to obtain serum for the evaluation of biochemical profiles (Table S2) and to carry out indirect ELISA (Table S1) for the detection of anti-*Leishmania* antibodies [37], or in tubes containing EDTA for complete blood counts (CBC) (Table S3 and S4) and PBMC isolation. Real-time PCR for the detection of *Leishmania* DNA was performed in blood samples from the included dogs in accordance with a previously described protocol using a calibration curve with DNA from 10^2 to 10^7 *Leishmani*a promastigotes [38].

2.4.2 Isolation of peripheral blood mononuclear cells

PBMCs from healthy controls and sick dogs were isolated by gradient centrifugation using Histopaque 1077 (Sigma, USA) in accordance with the manufacturer's recommendations. Isolated cells were then washed three times in phosphate buffered saline (PBS, pH 7.2) and suspended in RPMI 1640 (Sigma, USA) supplemented with inactivated 10% fetal bovine serum (FBS) (Gibco, USA), 0.03% L-glutamine (Sigma, USA), 100 IU/mL penicillin (Sigma, USA) and 100 mg/mL streptomycin (Sigma, USA).

2.4.3 Production of canine recombinant cytokines and soluble IL-10R1 receptor

Under the number of the Instituto Gonçalo Moniz Biosafety Technical Commission CTNbio-CQB # 0111/99, canine recombinant IL-12 was produced using a baculovirus-insect cell system as previously described [36]. Recombinant canine IL-2, IL-7, and the soluble extracytoplasmic domain of the IL-10 receptor alfa chain (sIL-10R1) were also obtained using a baculovirus-insect cell system. Briefly, DNA constructs encoding in tandem the signal peptide of GP64, present in AcMNPV, either mature IL-2 [39] or IL-7 (Genebank, accession DQ845341), or the sIL-10R1 (Genebank, accession XM_005620306.1) polypeptide, followed by a spacer (only in IL-2 and IL-7 constructs) and His-tag. All DNA constructs were synthetized by GenScript using codons optimized for translation in *Trichoplusia ni* (Piscataway,

USA). Bacmids (AcBacΔCC-GP64-IL-2E6H, AcBacΔCC-GP64-IL-7E6H, and AcBacΔCC-GP64-sIL-10R16H) were generated and purified from the DH10BacΔCC *Escherichia coli* strain [36]. The human IL-10R1 extracytoplasmic domain (Genebank, accession NP_001549) was used as a model to identify the canine sIL-10R1 polypeptide chain using a freely available online tool (http://www.sbc.su.se/~miklos/DAS/). Viral stocks (AcBacΔCC-GP64-IL-2E6H, AcBacΔCC-GP64-IL-7E6H and AcBacΔCC-GP64-sIL-10R16H) were titrated using an end-point method in Sf-9 cells (Invitrogen, Carlsbad, USA), and recombinant protein production and purification was performed as previously described [36]. Recombinant canine IL-15 was generated in the BL21(DE3) pLysS *E. coli* strain (Invitrogen) transformed by a plasmid DNA construct (*pRSET-mcaIL-15-opt-3S*) following the manufacturer's instructions, and subsequently purified by affinity chromatography [35] then refolded in 100 mM Tris-HCl, 500 mM glycine, 1 mM oxidized glutathione and 10 mM reduced glutathione (pH 8.0). To produce the protein, a DNA construct was synthetized encoding mature canine IL-15 (Genebank, accession XM_844053) using codons optimized for translation in *E. coli* (GenScript). In addition, endotoxin concentrations from all purified recombinant proteins were determined using Limulus Amebocyte Lysate (Gel-clot Method, Pyrotell, USA) [40], with resultantly low levels of endotoxins (<0.03 EU of endotoxin per mg of protein). All purified recombinant proteins were confirmed by Western blot assays using anti-his antibodies. Biological activity was verified as follows: both IL-2 and IL-15 were found to induce CTLL-2 cell proliferation [36]; IL-12 in combination with IL-2 promoted IFN-γ production in canine PBMCs [35]; IL-7 and IL-15 both stimulated the proliferation of canine PBMCs. Finally, sIL-10R1 was also shown to inhibit the proliferation of canine IL-10-treated MC/9 murine mast cells (ATCC CRL 8306) [41].

2.4.4 Lymphoproliferation assay

To assess the proliferation of lymphocytes, PBMCs were stained with carboxyfluorescein diacetate succinimidyl ester (2.5 μM) (CFSE, CellTrace, Invitrogen, UK) for 10 min at 37°C, in accordance with the manufacturer's recommendations and a previously published protocol [42]. Stained PBMCs were cultured on sterile 96-well plates (1×10^6/mL) in RPMI 1640 medium (Sigma, USA), either alone (negative control) or with the following canine recombinant proteins: rcaIL-2 (IL-2) (2 ng/mL), rcaIL-7 (IL-7) (40 ng/mL), rcaIL-12 (IL-12) (20 ng/mL), rcaIL-

15 (IL-15) (20 ng/mL), rcasIL-10R1 (sIL-10R1) (4 µg/mL). These recombinant proteins were tested in the following combinations: IL-12/IL-2, IL-12/IL-15, IL-12/sIL-10R1, IL-7/IL-15, or sIL-10R1 alone. Culturing was performed in the presence or absence of 20 µg/mL of soluble *L. infantum* antigens (SLA) (MHOM/BR/00/MERO2), as described by Lima et al., 2010 [43]. Cultures containing the mitogen phytohemagglutinin-M (PHA-M, 5 µL/mL) were used as positive controls. CFSE-unmarked PBMCs were used to verify CFSE staining. PBMCs were cultured for 5 days at 37°C under 5% CO2. Ten thousand events were acquired in a flow cytometer (BD C5 Accuri Flow Cytometer, USA) and data analysis was performed using BD Accuri C6 software, version 1.0 (BD Biosciences, CA, USA). A gate (R) was defined in the analysis to select cell populations with size and complexity similar to those of lymphocyte population and gate (M) for positive labeling (Fig. S1).

The assays were repeated in duplicate under the same conditions without CFSE staining. Supernatants were used to determine IFN-y and IL-10 levels by capture ELISA (R&D Systems, USA) following manufacturers recommendations. Pelleted cells were used to determine the expression of PD-1 and T-bet and GATA3 transcription factors by flow cytometry (described below).

2.4.5 Flow cytometric analysis for labeling PD-1, T-bet and GATA3 in PBMC

To detect PD-1 expression, PBMC were suspended in PBS containing 1% bovine serum albumin, 0.1% azide and 20% fetal bovine serum, for Fc receptor blockade (FcR). The cells were then mixed with PE-conjugated monoclonal antibodies anti-Human CD279 (PD-1) [19,20] or control isotype (BD Pharmigen, USA) following the manufacturer's instructions. Ten thousand events were acquired on channel FL2 of a flow cytometer and data analysis was performed as described in the lymphoproliferation assay (Fig. S2).

To evaluate T-bet and GATA3 expression, PBMC were fixed and permeabilized with commercial buffer (eBioscience Bioscience, USA) according to manufacturer's instructions. Cells were mixed with FITC conjugated anti-human monoclonal antibody T-bet (R&D Systems) and with PE conjugated anti-human monoclonal GATA3 (R&D Systems) or control isotypes (R&D Systems), following the manufacturer's instructions. The similarity of human (GenBank, accession #NP_037483 and CAA38877) and canine (XP_548164 and XP_005617214) T-bet and GATA3 proteins was 93 and 96% respectively. Ten thousand events were

acquired on channel FL1 and FL2 and cytometric analysis was performed as described in the lymphoproliferation assay (Fig. S3).

2.4.6 Statistical analysis

Statistical analysis was performed using the GraphPad Prism 6 software (GraphPad Software, Inc., La Jolla, CA, USA). Data was tested for normality (Shapiro-Wilk test). To compare values corresponding to lymphoproliferation, expression of PD-1 of T-bet and GATA3 and levels concentration of IL-10 and IFN-y within groups, Friedman test with Dunn's post-test was used. Results were considered significant when $p < 0.05$.

2.5 Results

2.5.1 Description of clinical and laboratory findings of the animals used in the study

Dogs selected from Araçatuba Zoonosis Control Center exhibited at least three signs compatible with CanL which included onychogryphosis and skin lesions (in 7 out of 10 animals), lymphadenopathy (6 out of 10), periocular lesions and cachexia (5 out of 10), alopecia (4 out of 10), and ear-tip lesions (3 out of 10). Negative control animals showed no clinical manifestations (Table S1). In each one of the 10 sick dogs and none of 5 negative control dogs, anti-*Leishmania* antibodies (ELISA OD, mean ± standard deviation, sick dogs: 0.88 ± 0.38 and negative control dogs: 0.10 ± 0.05, Table S1) (cut-off value: 0.27) and *Leishmania* DNA (real-time PCR median CT value: 27.0) (*Leishmania* DNA calibration curve CT values range: 13.2 to 33.7). Moreover, sick dogs presented a statistically significant reduction in RBC counts, hematocrit, hemoglobin concentration, serum albumin concentration, albumin/globulin ratio, and an increase in serum globulin concentration, as compared to negative controls dogs (Tables S2 and S3). Based on clinical signs and laboratory findings, sick dogs manifested leishmaniasis in clinical stage II, according to Solano-Gallego and collaborators [44].

2.5.2 Combinations of canine recombinant cytokines and/or soluble IL-10R1 receptor induce lymphoproliferation in naturally infected sick dogs

In CanL, dogs lack the ability to mount lymphoproliferative responses after stimulation of PBMC with *Leishmania* antigens [14,45,46]. In the attempt to develop protocols to restore lymphoproliferative responses in such dogs, combinations of IL-12/IL-2, IL-12/IL-15, IL-12/sIL-10R1, IL-15/IL-7 or sIL-10R1 alone were tested. PBMC from healthy dogs or dogs with leishmaniasis were cultured in the absence or presence of SLA in combination or not with the recombinant proteins or just with PHA for 5 days and the MFI of CFSE-labeled lymphocytes was determined under each condition. Reduction in CFSE-fluorescence in lymphocytes kept in each condition was used to determine cell proliferation, as compared fluorescence in lymphocytes maintained in culture medium alone [42]. In healthy dogs, lymphoproliferation occurred when PBMC were cultured with PHA or the combination of IL-12/IL-15 in absence or presence of SLA (Fig 1A). In *Leishmania*-infected sick dogs, although CFSE-labeled lymphocytes cultured with PHA showed some reduction in MFI, which was not statistically significant (Fig 1B). Interestingly, lymphocytes from sick dogs displayed proliferative response when cultured in each one of the combinations of recombinant proteins tested (IL-12/IL-2, IL-12/IL-15, IL-12/sIL-10R1, IL-15/IL-7) or sIL-10R1 alone, independently of presence of SLA in culture (Fig 1B).



Fig 1. Evaluation of lymphoproliferation in healthy control dogs or dogs with leishmaniasis following stimulation with canine recombinant proteins. CFSE-labeled PBMC were cultured for 5 days with medium alone (Medium) or medium with Soluble Leishmania Antigens (SLA) or phytohemagglutinin (PHA). In addition, PBMC cultured with medium alone or with SLA were stimulated with recombinant canine proteins, in combinations, IL-12/IL-2, IL-12/IL-15, IL-12/sIL-10R1, IL-15/IL-7, or sIL-10R1 isolated. CFSE-labeled lymphocyte mean fluorescence intensities were assessed by flow cytometry. Lymphocytes from healthy dogs (n=5) **(A)** and dogs with leishmaniasis (n=10) **(B)**. Horizontal bars represent median and interquartile 25 and 75 values of MFI. Each symbol represents datum of a single dog. Asterisk indicates significant differences (Friedman test with Dunn's multiple comparison, * $p < 0.05$).

2.5.3 Combination of IL-12/IL-2 or IL-12/IL-15 promotes decrease in lymphocyte PD-1 expression

Inability of lymphocytes from dogs with leishmaniasis to proliferate and produce Th1 cytokines, may be associated, at least in part, with an increase in PD-1 expression, which promotes apoptosis, during a progression of infection [19,20]. To assess if an interference with cytokine signaling could lead to reduction in expression of inhibitory molecules of the immune system in sick dogs, PBMC were cultured with or without SLA and/or combinations of recombinant canine cytokines, IL-12/sIL-10R1 or sIL-10R1 alone, and lymphocyte PD-1 expression was evaluated by flow cytometry. Lymphocytes from healthy dogs did not change PD-1 expression regardless of the addition of canine recombinant proteins to cultures with or without SLA (Fig 2A). However, lymphocytes from sick dogs exhibited a significant decrease

in PD-1 expression when the combinations of IL-12/IL-2 or IL-12/IL-15, in the absence or presence of SLA, were used in the cultures (Fig 2B). There was also some decrease in PD-1 expression while using IL-12/sIL-10R1, with or without SLA, but this was not statistically significant (Fig 2B).



Fig 2. Evaluation of PD-1 expression in lymphocytes from healthy control dogs and dogs with leishmaniasis after culturing the cells with canine recombinant proteins. PBMC were cultured for 5 days without any treatment (Medium) and in the presence of immunomodulatory canine recombinant proteins, in combination or not with Soluble Leishmania Antigens (SLA) and after this, labeled with PE-conjugated monoclonal antibodies Anti-Human CD279 (PD-1) and the mean fluorescence intensity was assessed by flow cytometry.**(A)** Lymphocytes of healthy dogs (n=5). **(B)** Lymphocytes of dogs with leishmaniasis (n=10). Horizontal bars represent median and interquartile 25 and 75 values of MFI. PBMC of the groups of dogs cultured in certain condition and symbols represent data of a single dog. Asterisk indicates significant differences (Friedman test with Dunn's multiple comparison, * $p < 0.05$).

2.5.4 Combination of IL-12/IL-15 induces an increase in T-bet without altering GATA-3 expression

Progression of leishmaniasis in dogs is associated with an incapacity to establish an effective cellular immune response (Th1) and by setting up an exacerbated humoral immune response (Th2) and/or development of an immunosuppressive state [8,47]. Immune system programming to generate Th1 or Th2 cell subsets involves expression of the master transcription factors T-bet and GATA3, respectively [48,49]. To identify conditions capable of modifying T helper cell

differentiation programming in dogs with leishmaniasis, PBMC were cultured with recombinant canine proteins with or without SLA and lymphocyte expression of T-bet and GATA3 were assessed by flow cytometry.

In PBMC from healthy dogs, the combinations of IL-12/IL-2 or IL-12/IL-15 without SLA generated a significant increase in lymphocyte T-bet expression that was inhibited by addition of SLA to the cultures (Fig 3A). On the other hand, in PMBC from sick dogs, IL-12/IL-15 induced a significant increase in lymphocytes T-bet expression, both in the absence or presence of SLA in the cultures (Fig. 3B). The other recombinant proteins tested, in combination or isolated, did not affect T-bet expression in the lymphocyte. None of the recombinant proteins evaluated, in combination with SLA or not, significantly altered the expression of GATA3 in lymphocytes of healthy or sick dogs (Fig 3C and 3D).



Fig 3. Effect of immunoregulatory canine recombinant proteins in combination (IL-12/IL-2, IL-12/IL-15, IL-12/sIL-10R1, IL-15/IL-7) or isolated (sIL-10R1) on the expression of the transcription factors T-bet and GATA3 of healthy dogs and with leishmaniasis. PBMC were cultured for 5 days without any treatment (Medium) and in the presence of immunomodulatory canine recombinant proteins in combination or not with Soluble Leishmania Antigens (SLA) and after this, labeled with FITC conjugated anti-human monoclonal antibody T-bet and with conjugated PE anti-human monoclonal GATA3 and the mean fluorescence intensity was assessed by flow cytometry. **(A and C)** Expression of T-bet and GATA3 respectively in lymphocytes of healthy dogs (n=5). **(B and D)** expression of T-bet and GATA3 respectively in lymphocytes of dogs with leishmaniasis (n=10). Horizontal bars represent median and interquartile 25 and 75 values of MFI. PBMC of the groups of dogs cultured in certain condition and symbols represent data of a single dog. Asterisk indicates significant differences (Friedman test with Dunn's multiple comparison, * $p < 0.05$).

2.5.5 Combinations of IL-12/IL-2, IL-12/IL15 or IL-12/sIL-10R1 provoke an increase in IFN-γ without altering IL-10 production

Driving long-term specific Th1 and preventing Th2 immune responses and/or an immunosuppressive state, may be useful in the treatment of CanL [8,18,47]. To determine if the recombinant proteins assessed herein show an impact in the production of cytokines mediating Th1 or immunosuppression in dogs with leishmaniasis, PBMC were cultured with combinations of IL-12/IL-2, IL-12/IL-15, IL-12/sIL-10R1, IL-15/IL-7 or sIL-10R1 alone, in the absence or the presence of SLA, and levels of IFN-γ and IL-10 in culture supernatants were measured by capture ELISA. The combinations of IL-12/IL-2 and IL-12/IL-15 induced a significant increase in IFN-γ levels in PBMC from healthy dogs (Fig 4A) and dogs with leishmaniasis (Fig 4B), both in the absence or presence of SLA. In addition, in sick dogs, the combination of IL-12/ sIL-10R1 promoted a significant increase in IFN-γ production, only in the presence of SLA (Fig 4D).

In PBMC from healthy dogs or sick dogs, none of the combinations IL-12/IL-2, IL-12/IL-15, IL-12/sIL-10R1, IL-15/IL-7 or sIL-10R1 alone, without or with SLA, caused a significant change in the levels of IL-10 (Fig 4C and D). Interestingly, there was a tendency for an increase in IL-10 levels in cell culture supernatant of sick dogs, especially in the presence of SLA in the cultures (Fig 4D). Finally, in PBMC from healthy dogs, detection of IL-10 was minimal when sIL-10R1 was used in culture in combination or not with IL-12, though this was not statistically significant



Fig 4. Effect of immunoregulatory canine recombinant proteins in combination (IL-12/IL-2, IL-12/IL-15, IL-12/sIL-10R1, IL-15/IL-7) or isolated (sIL-10R1) on the levels of IFN-γ and IL-10 in the culture supernatant from PBMC of healthy dogs and with leishmaniasis. PBMC were cultured for 5 days without any treatment (Medium) and in the presence of immunomodulatory canine recombinant proteins, in combination or not with Soluble Leishmania Antigens (SLA) and after this, IFN-γ and IL-10 concentration in the culture supernatant of the PBMC was determined by capture ELISA. **(A and C)** Production of IFN-γ and IL-10 respectively by the PBMC of healthy dogs (n=5). **(B and D)** Production of IFN-γ and IL-10 respectively by the PBMC of dogs with leishmaniasis (n=10). Horizontal bars represent median and interquartile 25 and 75 levels in pg/mL. PBMC of the groups of dogs cultured in certain condition and symbols represent data of a single dog. Asterisk indicates significant differences (Friedman test with Dunn's multiple comparison, * $p < 0.05$).

2.6 Discussion

Dogs naturally infected with *Leishmania infantum* exhibit an inability to mount a specific effective adaptive immune response, the so-called Th1 immune response with long-term memory. This is true in animals that progress in disease development, as well as in those that, after being treated with currently available drugs, exhibit disease relapse. In order to develop immunotherapeutic protocols, the present study evaluated a set of canine recombinant proteins capable of interfering with cytokine signaling pathways to determine the modulation of cellular responses in dogs with CanL.

Dogs with CanL develop T cell exhaustion, involving both $CD4^+$ and $CD8^+$ T lymphocytes [50], and thereby lose the ability to perform effector functions. In these animals, the capacity for lymphocytes to proliferate intensely under antigenic stimulation is one of the first functions lost [51]. To date, few authors have investigated the conditions capable of promoting lymphoproliferative responses against *Leishmania* antigens in CanL dogs [21,50]. In this study, several different combinations of recombinant proteins (IL-12/IL-2, IL-12/IL-15, IL-12/sIL-10R1, IL-15/IL-7 or sIL-10R1 alone) were shown to promote lymphoproliferation in dogs naturally infected with *L. infantum*. Lymphoproliferation was found to occur following incubation with IL-12/IL-2, IL-12/IL-15, IL-12/sIL-10R1, IL-15/IL-7, or sIL-10R1 alone, regardless of whether SLA was added to cultures or not. A probable explanation for this phenomenon could be the presence of *Leishmania* parasites within the PBMCs used in experimentation [52], more precisely in antigen-presenting cells (APCs), which does not require the addition of SLA to obtain an anti-parasitic proliferative response. In fact, *Leishmania* parasites were detectable in every blood sample from each diseased dog (Table S1).

Previously, some authors reported a significant increase or a tendency to increase lymphoproliferative response in dogs naturally infected by *L. infantum* by addition of IL-12 [21] or anti-IL-10 antibodies (antagonistic antibodies) and LSA to cultures of PBMC [50]. The data presented here also indicate that IL-12 and IL-10 blockade (by sIL-10R1) may contribute to the generation of lymphoproliferative response in CanL dogs. Human cytokines homologous to canine cytokines evaluated herein are capable of stimulating the proliferation of resting and/or activated peripheral blood lymphocytes (PBLs) in healthy individuals. Depending on circumstances, such as cell activation status, cytokines concentration and microenvironment, each of these cytokines preferentially stimulates certain subpopulations of lymphocytes. Human IL-12, IL-2, IL-15 and IL-7, tend to stimulate proliferation of: a) NK, CD4 and $CD8^+$ T cells, b) T and NK cells, c) NK cells, naïve, effector memory (TEM) and central memory (TCM) T cells, and d) naïve T cells, TCM and TEM cells, respectively [53–58]. In future experiments, the subpopulations of lymphocytes stimulated to expand by the recombinant canine proteins tested here will be determined.

T cell exhaustion state results from inhibitory signals received by these cells. PD-1 cell surface receptor and its PD-L1 and PD-L2 ligands constitute main signaling pathway of this process. PD-1 binding to its ligands leads to recruitment of SHP-2 phosphatase, dephosphorylation of molecules such as PI3K and Zap70, and cell inactivation [59]. PD-1 protein expression becomes progressively higher as the exhaustion process intensifies in T cells [51]. Interestingly, none of the combinations of recombinant proteins or sIL-10R1 caused significant alteration in PD1 expression of lymphocytes from the healthy negative control dogs. However, the IL-12/IL-2 and IL-12/IL-15 elicited a significant decrease in PD-1 protein expression in lymphocytes from dogs with CanL. In these animals, IL-12/sIL-10R1 and sIL-10R1, provoked a reducing trend or no changing in expression of PD-1, respectively. These data suggest that, under the conditions in which recombinant proteins were tested, IL-12 was responsible for promoting the reduction in PD-1 expression. In a previous study, stimulation with IL-12 was shown to cause reduction in PD-1 and increase in T-bet expression, and arouse effector function in $CD8^+$ T lymphocytes, rescuing these cells from exhaustion in human patients infected with hepatitis B virus [60]. IL-12 probably modulates PD-1 expression through induction in T-bet transcription factor [61,62].

Depending upon combinations of several stimuli, including from TCR signaling, cytokines, costimulatory, co-inhibitory, adhesion molecules, and/or chemokines, naïve T lymphocytes may initiate one of various gene expression programs, resulting in cell differentiation and acquisition of certain functional capacities [63,64]. The differentiation genetic programs of Th1 and Th2 lymphocytes involves the expression of the master transcription factors T-bet and GATA3 [65,66] respectively. These transcription factors negatively modulate one another [67]. To date, there are a limited number of reports on the expression of T-bet or GATA-3 in dogs. To the best of our knowledge, this is the first study to describe expression of T-bet and GATA-3 proteins in CanL dogs. Interestingly, IL-12/IL-2 and IL-12/IL-15 promoted an increase in T-bet expression in healthy negative control dog lymphocytes, which was inhibited by the addition of SLA, suggesting some suppressive SLA activity.

In lymphocytes from dogs with CanL, only IL-12/IL-15 induced an increase in T-bet expression, independently of addition of SLA in the cultures. IL-15 may have elicited an enhancement in IL-12Rβ1 expression [68] resulting a higher level of IL-12 signaling, and as consequence, increased production T-bet. None of the recombinant canine or sIL-10R1 protein combinations modified the expression of GATA-3 in healthy control dogs or dogs with leishmaniasis. Expression of T-bet and GATA-3 mRNA was previously evaluated in spleen [69] and skin [70] from dogs with leishmaniasis. In these animals, expression of T-bet and GATA-3 mRNAs in spleen and skin was shown to be increased or unchanged, respectively [69,70] compared to uninfected animals. In our study, no significant differences were found in T-bet and GATA-3 protein expression in PBLs between dogs with CanL and healthy negative controls.

IFN-γ and IL-10 are able to stimulate or attenuate defense mechanisms in macrophages and contribute to control or favor infection in dogs naturally inoculated with *L. infantum* [18]. Several cells of the innate or adaptive immune system can secrete IFN-γ or IL-10 [71,72]. Among the cells of the adaptive immune system, Th1 and CD8 T lymphocytes are the IFN-γ-producing cells [71]. On the other hand, several subpopulations of lymphocytes, including Th1, Th2 and Th1y cells can produce IL-10 [72]. The negative control dogs exhibited significant increase in IFN-γ production when PBMC were stimulated with IL-12/IL-2 or IL-12/IL-15 in the absence and presence of SLA, respectively. However, PMBCs from these animals also

showed a tendency to increase IFN-γ production following incubation with: a) IL-12/sIL-10R1 along to addition of SLA or not, or b) IL-7/IL-15 without addition of LSA, though not statistically significant.

Interestingly, dogs with CanL also exhibited significant increase in IFN-γ production by PBMCs cultured with IL-12/IL-2 or IL-12/IL-15 combination with addition of LSA or not. Further, PBMCs of these animals produced higher levels of IFN-γ after stimulation with IL-12/sIL-10R1 and addition of SLA in the cultures. Our findings suggest that IL-12 associated with an additional stimulus may lead to efficient production of IFN-γ in dogs [35,36] including with CanL, and is consistent with the data reported by Ayali et al., 2005 [21], that showed significant increase in IFN-γ production in CanL dog PBMCs by stimulation with IL-12 and SLA. Moreover, the data showing that IL-12/sIL-10R1 or sIL-10R1 have only limited effect and no effect in promoting increase in IFN-γ production, respectively, corroborate the findings of Esch et al., 2014, who reported that blockade of IL-10 signaling does not boost IFN-γ synthesis in either $CD4^+$ or $CD8^+$ T lymphocytes in dogs with leishmaniasis [50].

Healthy negative controls and dogs with leishmaniasis revealed an increase in IL-10 production, though statistically insignificant, after stimulation with either IL-12/IL-2, IL-12/IL-15 in cultures in which SLA were added or not. Curiously, sIL-10R1 alone or IL-12/sIL-10R1 virtually prevented detection of IL-10 in cultures from negative control dogs. It is possible that sIL-10R1 has bound to IL-10 and, by doing so, prevented the cytokine binding to antibodies in the detection assay. In future experiments, evaluation of production of IL-10 will be carried out by intracellular detection using flow cytometry.

In conclusion, among the various combinations of canine recombinant proteins and casIL-10R1 alone capable of interfering with cytokine signaling pathways tested, IL-12/IL-15 proteins have shown to promote significant lymphoproliferative response, increase in T-bet without altering GATA-3 expression, increase in IFN-γ without changing IL-10 production. These data suggest that IL-12/IL-15 may enhance cellular immune responses and contribute to reprogramming of immune responses, being potentially useful developing effective treatments to CanL.



Fig 5. Graphical abstract. Effects of combined stimulation of IL-12 and IL-15 restores lymphoproliferative response, decreases PD-1 expression and increases T-bet expression and IFN-γ production.

2.7 Acknowledgment

The authors would like to thank Flavia Mari Yamamoto for helping with the experiments. The authors also thank the following institutions for financial support: Foundation for Research Support of the State of São Paulo (FAPESP) process 2017/10906-8, National Council for Scientific and Technological Development (CNPq)/INCT-DT process #573839/2008-5, and CNPq-PROEP process #400913/2013-5 for the financial support. This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001 (Financed students: SFC, MOSM, LMM, GLV, JBP, GTR,COS, BMNO). Finally, the authors thank the Program for Technological Development in Tools for Health-PDTIS-FIOCRUZ for the use of its facilities.

REFERENCE

1. Murray HW. Interleukin 10 receptor blockade - Pentavalent antimony treatment in experimental visceral leishmaniasis. **Acta Trop**. 2005;93: 295–301. doi:10.1016/j.actatropica.2004.11.008

2. WHO. Investing to overcome the global impact of neglected tropical diseases.

In: **World Health Organization [Internet]**. 2015 [cited 21 Jan 2019]. Available: https://www.who.int/neglected_diseases/9789241564861/en/

3. Ministério da Saúde (BR). **Leishmaniose Visceral - Situação Epidemiológica - Dados [Internet]**. 2019 [cited 20 Jan 2019]. Available: http://portalms.saude.gov.br/saude-de-a-z/leishmaniose-visceral/11334-situacao-epidemiologica-dados

4. Moreno J, Alvar J. Canine leishmaniasis : epidemiological risk and the experimental model. **Trends Parasitol**. 2002;18: 399–405. doi.org/10.1016/S1471-4922(02)02347-4

5. Teixeira-Neto RG, da Silva ES, Nascimento RA, Belo VS, de Oliveira C di L, Pinheiro LC, et al. Canine visceral leishmaniasis in an urban setting of Southeastern Brazil: an ecological study involving spatial analysis. **Parasit Vectors**. 2014;7: 485. doi:10.1186/s13071-014-0485-7

6. Costa DNCC, Bermudi PMMB, Rodas LAC, Nunes CM, Hiramoto RM, Tolezano JE, et al. Human visceral leishmaniasis and relationship with vector and canine control measures. **Rev Saude Publica**. 2018;52: 92. doi:10.11606/S1518-8787.2018052000381

7. Nunes CM, Pires MM, da Silva KM, Assis FD, Filho JG, Perri SHV. Relationship between dog culling and incidence of human visceral leishmaniasis in an endemic area. **Vet Parasitol**. 2010;170: 131–133. doi:10.1016/j.vetpar.2010.01.044

8. Alvar J, Cañavate C, Molina R, Moreno J, Nieto J. Canine leishmaniasis. **Adv Parasitol**. 2004;57: 1–88. doi:10.1016/S0065-308X(04)57001-X

9. Reguera RM, Morán M, Pérez-Pertejo Y, García-Estrada C, Balaña-Fouce R. Current status on prevention and treatment of canine leishmaniasis. **Vet Parasitol**. 2016;227: 98–114. doi:10.1016/j.vetpar.2016.07.011

10. dos Santos Nogueira F, Avino VC, Galvis-Ovallos F, Pereira-Chioccola VL, Moreira MAB, Romariz APPL, et al. Use of miltefosine to treat canine visceral leishmaniasis caused by *Leishmania infantum* in Brazil. **Parasit Vectors**. 2019;12: 79. doi:10.1186/s13071-019-3323-0

11. Travi BL, Cordeiro-da-Silva A, Dantas-Torres F, Miró G. Canine visceral leishmaniasis: Diagnosis and management of the reservoir living among us. **PLoS Negl Trop Dis**. 2018;12: 1–13. doi:10.1371/journal.pntd.0006082

12. Ribeiro RR, Michalick MSM, da Silva ME, dos Santos CCP, Frézard FJG, da Silva SM. Canine Leishmaniasis: An Overview of the Current Status and Strategies for Control. **Biomed Res Int**. 2018;2018: 1–12. doi:10.1155/2018/3296893

13. Santos-Gomes GM, Rosa R, Leandro C, Cortes S, Romão P, Silveira H. Cytokine expression during the outcome of canine experimental infection by *Leishmania infantum*. **Vet Immunol Immunopathol**. 2002;88: 21–30. doi:10.1016/S0165-2427(02)00134-4

14. Pinelli E, Wagenaar J, Bernadina W, Pinelli E, Killick-kendrick R, Wagenaar J, et al. Cellular and Humoral Immune Responses in Dogs Experimentally and Naturally Infected with *Leishmania infantum.* **Infect Immun**. 1994;62: 229-235(7). doi:0019-9567/94/$04.00+0

15. Pinelli E, Gonzalo RM, Boog CJP, Rutten VPMG, Gebhard D, Del Real G, et al. *Leishmania infantum*-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocompatibility complex-restricted manner. **Eur J Immunol**. 1995;25: 1594–1600. doi:10.1002/eji.1830250619

16. Alves CF, de Amorim IFG, Moura EP, Ribeiro RR, Alves CF, Michalick MS, et al. Expression of IFN-γ, TNF-α, IL-10 and TGF-β in lymph nodes associates with parasite load and clinical form of disease in dogs naturally infected with *Leishmania (Leishmania) chagasi*. **Vet Immunol Immunopathol**. 2009;128: 349–358. doi:10.1016/j.vetimm.2008.11.020

17. Panaro MA, Acquafredda A, Lisi S, Lofrumento DD, Mitolo V, Sisto M, et al. Nitric oxide production by macrophages of dogs vaccinated with killed *Leishmania infantum* promastigotes. **Comp Immunol Microbiol Infect Dis**. 2001;24: 187–95. Available: http://www.ncbi.nlm.nih.gov/pubmed/11440191

18. Boggiatto PM, Ramer-Tait AE, Metz K, Kramer EE, Gibson-Corley K, Mullin K, et al. Immunologic indicators of clinical progression during canine *Leishmania infantum* infection. **Clin Vaccine Immunol**. 2010;17: 267–273. doi:10.1128/CVI.00456-09

19. Chiku VM, Silva KLO, de Almeida BFM, Venturin GL, Leal AAC, de Martini CC, et al. PD-1 function in apoptosis of T lymphocytes in canine visceral leishmaniasis. **Immunobiology**. 2016;221: 879–888. doi:10.1016/j.imbio.2016.03.007

20. Oliveira Silva KL, Marin Chiku V, Luvizotto Venturin G, Correa Leal AA, de Almeida BF, De Rezende Eugenio F, et al. PD-1 and PD-L1 regulate cellular immunity in canine visceral leishmaniasis. **Comp Immunol Microbiol Infect Dis**. 2019;62: 76–87. doi:10.1016/j.cimid.2018.12.002

21. Bacellar O, Brodskyn C, Guerreiro J, Barral-Netto M, Costa CH, Coffman RL, et al. Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis. **J Infect Dis**. 1996;173: 1515–8. doi:10.1093/infdis/173.6.1515

22. Strauss-Ayali D, Baneth G, Shor S, Okano F, Jaffe CL. **I**nterleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in *Leishmania infantum*-infected dogs**. Int J Parasitol**. 2005;35: 63–73. doi:10.1016/j.ijpara.2004.10.015

23. Carvalho EM, Bacellar O, Brownell C, Regis T, Coffman RL, Reed SG. Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. **J iImunology**. 1994;152: 5949–56. Available:

http://www.ncbi.nlm.nih.gov/pubmed/8207220

24. Bacellar O, D'Oliveira A, Jerônimo S, Carvalho EM. IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. **Cytokine**. 2000;12: 1228–1231. doi:10.1006/cyto.2000.0694

25. Ghalib HW, Whittle JA, Kubin M, Hashim FA, El-Hassan AM, Grabstein KH, et al. IL-12 enhances Th1-type responses in human *Leishmania donovani* infections. **J Immunol**. 1995;154: 4623–9. Available: http://www.ncbi.nlm.nih.gov/pubmed/7722314

26. Milano S, Di Bella G, D'Agostino P, Barbera C, Caruso R, La Rosa M, et al. IL-15 in human visceral leishmaniasis caused by *Leishmania infantum*. **Clin Exp Immunol**. 2002;127: 360–365. doi:10.1046/j.1365-2249.2002.01749.x

27. Gautam S, Kumar R, Maurya R, Nylén S, Ansari N, Rai M, et al. IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. **J Infect Dis**. 2011;204: 1134–1137. doi:10.1093/infdis/jir461

28. dos Santos LR, Barrouin-Melo SM, Chang Y-F, Olsen J, McDonough SP, Quimby F, et al. Recombinant single-chain canine interleukin 12 induces interferon gamma mRNA expression in peripheral blood mononuclear cells of dogs with visceral leishmaniasis. **Vet Immunol Immunopathol**. 2004;98: 43–48. doi:10.1016/j.vetimm.2003.10.006

29. Gessner A, Vieth M, Will A, Schröppel K, Röllinghoff M. Interleukin-7 enhances antimicrobial activity against *Leishmania major* in murine macrophages. **Infect Immun**. 1993;61: 4008–12. Available: http://www.ncbi.nlm.nih.gov/pubmed/8359927

30. Marchi LHL, Paschoalin T, Travassos LR, Rodrigues EG. Gene therapy with interleukin-10 receptor and interleukin-12 induces a protective interferon-γ-dependent response against B16F10-Nex2 melanoma. **Cancer Gene Ther**.

Nature Publishing Group; 2011;18: 110–122. doi:10.1038/cgt.2010.58

31. Nielsen CM, Wolf A-S, Goodier MR, Riley EM. Synergy between Common γ Chain Family Cytokines and IL-18 Potentiates Innate and Adaptive Pathways of NK Cell Activation. **Front Immunol**. 2016;7. doi:10.3389/fimmu.2016.00101

32. Chen X, O'Donnell MA, Luo Y. Dose-dependent synergy of Th1-stimulating cytokines on bacille Calmette-Guérin-induced interferon-γ production by human mononuclear cells. **Clin Exp Immunol**. 2007;149: 178–185. doi:10.1111/j.1365-2249.2007.03413.x

33. Bartee E, McFadden G. Cytokine synergy: An underappreciated contributor to innate anti-viral immunity. **Cytokine**. 2013;63: 237–240. doi:10.1016/j.cyto.2013.04.036

34. Yoshikai Y, Nishimura H. The role of interleukin 15 in mounting an immune response against microbial infections. **Microbes Infect**. 2000;2: 381–389. doi:10.1016/S1286-4579(00)00329-4

35. Pereira AM, De Pinheiro CGM, Dos Santos LR, Teixeira NC, Chang YF, Pontes-De-Carvalho LC, et al. Requirement of dual stimulation by homologous recombinant IL-2 and recombinant IL-12 for the in vitro production of interferon gamma by canine peripheral blood mononuclear cells. **BMC Res Notes**. 2014;7: 1–10. doi:10.1186/1756-0500-7-460

36. De Pinheiro CGM, Pedrosa MDO, Teixeira NC, Ano Bom APD, Van Oers MM, Oliveira GGDS. Optimization of canine interleukin-12 production using a baculovirus insect cell expression system Biotechnology. **BMC Res Notes**. BioMed Central; 2016;9: 1–11. doi:10.1186/s13104-016-1843-7

37. Lima VMF, Gonçalves ME, Ikeda FA, Luvizotto MCR, Feitosa MM. Anti-leishmania antibodies in cerebrospinal fluid from dogs with visceral leishmaniasis. **Braz J Med Biol Res**. 2003;36. Available: http://www.scielo.br/pdf/bjmbr/v36n4/4605.pdf

38. Perosso J, Silva KLO, Ferreira SÍ de S, Avanço SV, dos Santos PSP, Eugênio F de R, et al. Alteration of sFAS and sFAS ligand expression during canine visceral leishmaniosis. **Vet Parasitol**. 2014;205: 417–423. doi:10.1016/j.vetpar.2014.09.006

39. Dunham SP, Argyle DJ, Onions DE. The isolation and sequence of canine interleukin-2. **DNA Seq**. 1995;5: 177–180. doi:10.3109/10425179509029359

40. USP (2011) **Chapter ,85., Bacterial Endotoxins Test [Internet]**. Available: http://www.usp.org/harmonization-standards/pdg/general-methods/bacterial-endotoxins

41. Tan JC, Braun S, Rong H, DiGiacomo R, Dolphin E, Baldwin S, et al. Characterization of Recombinant Extracellular Domain of Human Interleukin-10 Receptor. **J Biol Chem**. 1995;270: 12906–12911. doi:10.1074/jbc.270.21.12906

42. Lyons AB, Parish CR. Determination of lymphocyte division by flow cytometry. **J Immunol Methods**. 1994;171: 131–137. doi:10.1016/0022-1759(94)90236-4

43. de Lima VMF, Fattori KR, Michelin A de F, Neto L da S, Vasconcelos R de O. Comparison between ELISA using total antigen and immunochromatography with antigen rK39 in the diagnosis of canine visceral leishmaniasis. **Vet Parasitol**. 2010;173: 330–333. doi:10.1016/j.vetpar.2010.07.012

44. Solano-Gallego L, Koutinas A, Miró G, Cardoso L, Pennisi MG, Ferrer L, et al. Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis. **Vet Parasitol**. 2009. pp. 1–18. doi:10.1016/j.vetpar.2009.05.022

45. Martínez-Moreno A, Moreno T, Martínez-Moreno FJ, Acosta I, Hernández S. Humoral and cell-mediated immunity in natural and experimental canine leishmaniasis. **Vet Immunol Immunopathol**. 1995;48: 209–220. doi:10.1016/0165-2427(95)05434-8

46. Rhalem A, Sahibi H, Guessous-Idrissi N, Lasri S, Natami A, Riyad M, et al. Immune response against Leishmania antigens in dogs naturally and experimentally infected with *Leishmania infantum*. **Vet Parasitol**. 1999;81: 173–84. Available: http://www.ncbi.nlm.nih.gov/pubmed/10190861

47. Baneth G, Koutinas AF, Solano-Gallego L, Bourdeau P, Ferrer L. Canine leishmaniosis – new concepts and insights on an expanding zoonosis: part one. **Trends Parasitol**. 2008;24: 324–330. doi:10.1016/j.pt.2008.04.001

48. Pai S-Y, Truitt ML, Ho I-C. GATA-3 deficiency abrogates the development and maintenance of T helper type 2 cells. **Proc Natl Acad Sci**. 2004;101: 1993–1998. doi:10.1073/pnas.0308697100

49. Mullen AC. Role of T-bet in Commitment of TH1 Cells Before IL-12-Dependent Selection. **Science**. 2001;292: 1907–1910. doi:10.1126/science.1059835

50. Esch KJ, Juelsgaard R, Martinez PA, Jones DE, Christine A. PD-1-mediated T cell exhaustion during visceral leishmaniasis impairs phagocyte function Kevin. **J Immunol**. 2013;191: 5542–5550. doi:10.4049/jimmunol.1301810.PD-1-mediated

51. Wherry EJ. T cell exhaustion. **Nat Immunol**. 2011;12: 492–9. Available: http://www.ncbi.nlm.nih.gov/pubmed/21739672

52. Paraguai de Souza E, Esteves Pereira AP, Machado FC, Melo MF, Souto-Padrón T, Palatnik M, et al. Occurrence of *Leishmania donovani* parasitemia in plasma of infected hamsters. **Acta Trop**. 2001;80: 69–75. Available: http://www.ncbi.nlm.nih.gov/pubmed/11495646

53. Geginat J, Sallusto F, Lanzavecchia A. Cytokine-driven Proliferation and Differentiation of Human Naive, Central Memory, and Effector Memory CD4. **J Exp Med**. 200; 194:1711-9. doi:10.1084/jem.194.12.1711

54. Welch PA, Namen AE, Goodwin RG, Armitage R, Cooper MD. Human IL-7: a

novel T cell growth factor. **J Immunol**. 1989;143: 3562–7. Available: http://www.ncbi.nlm.nih.gov/pubmed/2555412

55. Perussia B, Chan SH, D'Andrea A, Tsuji K, Santoli D, Pospisil M, et al. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells. **J Immunol**. 1992;149: 3495–502. Available: http://www.ncbi.nlm.nih.gov/pubmed/1358972

56. Gately MK, Desai BB, Wolitzky AG, Quinn PM, Dwyer CM, Podlaski FJ, et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). **J Immunol**. 1991;147: 874–82. Available: http://www.ncbi.nlm.nih.gov/pubmed/1713608

57. Baume DM, Robertson MJ, Levine H, Manley TJ, Schow PW, Ritz J. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells. **Eur J Immunol**. 1992;22: 1–6. doi:10.1002/eji.1830220102

58. Winkelstein A, Weaver LD, Salva N, Machen LL. Interleukin-2-induced lymphoproliferative responses. **Cancer Immunol Immunother**. 1990;32: 110–6. Available: http://www.ncbi.nlm.nih.gov/pubmed/1705176

59. Jin H-T, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. **Curr Top Microbiol Immunol**. 2011;350: 17–37. doi:10.1007/82_2010_116

60. Schurich A, Pallett LJ, Lubowiecki M, Singh HD, Gill US, Kennedy PT, et al. The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T Cells. **PLoS Pathog**. 2013; 9: e1003208. doi:10.1371/journal.ppat.1003208

61. Kao C, Oestreich KJ, Paley MA, Crawford A, Angelosanto JM, Ali MA, et al. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. **Nat**

Immunol. 2011;12: 663–671. doi:10.1038/ni.2046

62. Szabo SJ, Sullivan BM, Sternmann C, Satoskar AR, Sleckman BP, Glimcher LH. Distinct effects of T-bet in Th1 lineage commitment and IFN-γ production in CD4 and CD8 T cells. **Science**. 2002; 295: 338–342. doi:10.1126/science.1065543

63. Murphy KM, Stockinger B. Effector T cell plasticity: flexibility in the face of changing circumstances. **Nat Immunol**. 2010;11: 674–680. doi:10.1038/ni.1899

64. Luckheeram RV, Zhou R, Verma AD, Xia B. CD4 + T Cells: Differentiation and Functions. **Clin Dev Immunol**. 2012;2012: 1–12. doi:10.1155/2012/925135

65. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. **Cell**. 1997;89: 587–96. Available: http://www.ncbi.nlm.nih.gov/pubmed/9160750

66. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. **Cell**. 2000;100: 655–69. Available: http://www.ncbi.nlm.nih.gov/pubmed/10761931

67. Jenner RG, Townsend MJ, Jackson I, Sun K, Bouwman RD, Young RA, et al. The transcription factors T-bet and GATA-3 control alternative pathways of T-cell differentiation through a shared set of target genes. **Proc Natl Acad Sci**. 2009;106: 17876–17881. doi:10.1073/pnas.0909357106

68. Wu C-Y, Warrier RR, Wang X, Presky DH, Gately MK. Regulation of interleukin-12 receptor β1 chain expression and interleukin-12 binding by human peripheral blood mononuclear cells. **Eur J Immunol**. 1997;27: 147–154. doi:10.1002/eji.1830270122

69. Strauss-Ayali D, Baneth G, Jaffe CL. Splenic immune responses during canine visceral leishmaniasis. **Vet Res**. 2007;38: 547–564.

doi:10.1051/vetres:2007015

70. Menezes-Souza D, Corrêa-Oliveira R, Guerra-Sá R, Giunchetti RC, Teixeira-Carvalho A, Martins-Filho OA, et al. Cytokine and transcription factor profiles in the skin of dogs naturally infected by *Leishmania (Leishmania) chagasi* presenting distinct cutaneous parasite density and clinical status. **Vet Parasitol**. 2011;177: 39–49. doi:10.1016/j.vetpar.2010.11.025

71. Castro F, Cardoso AP, Gonçalves RM, Serre K, Oliveira MJ. Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion. **Front Immunol**. 2018;9. doi:10.3389/fimmu.2018.00847

72. Gabryšová L, Howes A, Saraiva M, O'Garra A. The Regulation of IL-10 Expression. **Curr Top Microbiol Immunol**. 2014;380:157-190. doi:10.1007/978-3-662-43492-5_8

2.8 Support information



S1 Fig. Histogram representative of flow cytometric analysis of lymphoproliferative response. PBMC were cultured for 5 days without any treatment (Medium) **(A)**, in the presence of the phytohemagglutinin mitogen (PHA) or combined immunomodulatory recombinant proteins IL-2/IL-12 **(B)**, IL-12/IL15 **(C)**, IL-12/sIL-10R1 **(D)**, IL-7/IL-15 **(E)** and alone sIL-10R1 **(F)** in combination or not with Soluble Leishmania Antigen (SLA) and, after this, mean intensity fluorescence of CFSE was assessed by flow cytometry. Gate in R marking of lymphoid cells, gate in M marking of lymphoproliferation and PD1, peak red PD1 positive and peak black Iso-Control. All experiments included 15 dogs, 5 healthy dogs and 10 dogs with leishmaniasis.



S2 Fig. Histogram representative of the flow cytometric analysis of the labeling of PD-1. PBMC were cultured for 5 days without any treatment (Medium) **(A)**, in the presence of the combined immunomodulatory recombinant proteins IL-2/IL-12 **(B)**, IL-12/IL15 **(C)**, IL-12/sIL-10R1 **(D)**, IL-7/IL-15 **(E)** and isolated sIL-10R1 **(F)** in combination or not with Soluble Leishmania Antigens (SLA) and after this, labeled with PE-conjugated monoclonal antibodies: Anti-Human CD279 (PD-1) and the mean intensity fluorescence was assessed by flow cytometry. Gate in R marking of lymphoid cells, gate in M marking of lymphoproliferation and PD1, peak red PD1 positive and peak black Iso-Control. All experiments included 15 dogs, 5 healthy dogs and 10 dogs with leishmaniasis.



S3 Fig. Histogram representative of the flow cytometric analysis of the labeling of T-Bet and GATA3 transcription factors. PBMC were cultured for 5 days without any treatment (Medium) **(A)**, in the presence of the combined immunomodulatory recombinant proteins IL-2/IL-12 **(B)**, IL-12/IL15 **(C)**, IL-12/sIL-10R1 **(D)**, IL-7/IL-**15 (E)** and isolated sIL-10R1 (**F)** in combination or not with Soluble Leishmania Antigens (SLA) and after this, labeled with FITC conjugated anti-human monoclonal antibody T-bet and with PE conjugated anti-human monoclonal GATA-3 and the mean intensity fluorescence was assessed by flow cytometry. Gate in R marking of lymphoid cells, gate in M marking of lymphoproliferation and PD1, peak red PD1 positive and peak black Iso-Control. All experiments included 15 dogs, 5 healthy dogs and 10 dogs with leishmaniasis.

Table S1. Clinical findings, detection of anti-*Leishmania* antibodies and *Leishmania* DNA.

Dog	CanL			Control		
	Clinical findings	**ELISA OD values***	**Real-time PCR CT values****	**Clinical findings**	**ELISA OD values***	**Real-time PCR CT values****
1	Alopecia, lymphadenopathy, periocular lesions, onychogryphosis	0.956	27.89	None	0.143	BCT
2	Cachexia, periocular lesions, onychogryphosis,skin lesions	0.506	26.38	None	0.129	BCT
3	Cachexia, ear-tip injuries, periocular lesions, onychogryphosis	1.131	32.11	None	0.055	BCT
4	Alopecia, skin lesions, lymphadenopathy	1.238	29.34	None	0.041	BCT
5	Cachexia, onychogryphosis periocular lesions, skin lesions	0.355	26.83	None	0.121	BCT
6	Alopecia, cachexia, skin lesions, lymphadenopathy	0.711	27.11	-	-	-
7	Cachexia, lymphadenopathy, onychogryphosis, skin lesions	1.315	24.23	-	-	-
8	Ear-tip injuries, lymphadenopathy, onychogryphosis, skin lesions	0.929	26.46	-	-	-
9	Lymphadenopathy, onychogryphosis, skin lesions	0.368	25.04	-	-	-
10	Alopecia, onychogryphosis, ear-tip injuries, periocular lesions	1.323	31.78	-	-	-
Mean± SD	**-**	**0.883± 0.379**	**27.72± 2.63**	**-**	**0.098± 0.046**	**-**

CanL: canine leishmaniasis. Control: healthy negative control. OD: optical density. *ELISA cut-off value: OD 0.270. CT: threshold cycle. BCT: below CT value after 40 amplification cycles. **Real-time PCR calibration curve carried out with DNA from 10^2 to 10^7 *Leishmania* promastigotes gave CT values from 13.23 to 33.74. Real-time PCR amplification specificity was confirmed by determination of melting point in each reaction.

Table S2. Sera biochemical profile.

Dogs #		Albumin	Globulin	Total protein	Uric Acid	Creatinine	Urea	ALT	AST	GGT
	Ref. values	**26-33 g/L**	**24-44 g/L**	**54-71 g/L**	**0-2 mg/dl**	**0.5-1.5 mg/dL**	**1.67-8.33 mmol/L**	**21-102 UI/L**	**23-66 UI/L**	**1.2-6.4 UI/L**
CanL 1		16.4	68.7	85.1	0.6	0.9	3.8	63.0	63.2	2.3
CanL 2		8.6	43.2	51.9	2.4	0.5	6.6	54.1	65.6	7.9
CanL 3		15.6	55.2	70.9	0.5	0.7	5.3	84.3	66.7	1.0
CanL 4		20.9	62.8	83.7	0.7	1.1	5.0	36.6	65.3	0.7
CanL 5		8.8	65.9	74.7	0.8	0.7	7.3	120.6	116.3	0.7
CanL 6		11.8	84.4	96.2	3.7	0.8	10.6	192.1	195.6	0.2
CanL 7		13.5	67.2	80.7	2.0	1.1	10.0	81.0	69.3	0.5
CanL 8		14.1	65.7	79.8	5.3	0.5	5.4	38.8	42.6	4.3
CanL 9		9.9	32.9	42.8	2.2	0.7	3.1	31.5	40.7	8.6
CanL 10		12.4	62.6	75.0	1.7	0.6	2.7	24.1	44.2	4.2
	Mean± SD	**13.2± 3.8[a]**	**60.9± 14.3[a]**	**74.1± 15.9[a]**	**2.0± 1.5[a]**	**0.8± 0.2[a]**	**6.0± 2.7[a]**	**72.6± 51.3[a]**	**77.0± 46.9[a]**	**3.0± 3.1[a]**
Control 1		29.3	30.6	60.0	2.0	1.4	9.2	77.4	46.0	2.5
Control 2		33.7	29.3	63.0	1.5	1.1	6.0	47.8	45.3	4.5
Control 3		29.1	23.9	53.0	0.9	1.1	4.2	52.3	29.1	2.4
Control 4		21.6	39.4	61.1	1.6	1.0	5.2	63.5	58.1	2.5
Control 5		30.1	30.6	60.7	1.6	1.3	7.6	20.1	43.1	2.8
	Mean± SD	**28.8± 4.4[b]**	**30.8± 5.6[b]**	**59.6± 3.8[b]**	**1.5± 0.4[a]**	**1.2± 0.2[a]**	**6.4± 2.0[a]**	**52.2± 21.3[a]**	**44.3± 10.3[a]**	**2.9± 0.9[a]**

CanL: canine leishmaniasis. Control: healthy negative control. ALT: alanine aminotransferase, AST: aspartate aminotransferase, GGT: gamma glutamyl transferase. a,b Equal letters in the same colum indicate no statistical difference using unpaired t-test

Table S3. Red blood cells parameters.

Dog #		RBC	Ht	Hemoglobin	MCV	MCHC
	Referenc e values	5.5-8.5 x10^{6}/μL	37-55 %	12-18 g/dL	60-77 fL	32-36 %
CanL 1		3.75	24.0	7.5	64.2	31.2
CanL 2		4.08	24.5	7.7	60.1	31.4
CanL 3		3.20	24.7	7.1	77.2	28.7
CanL 4		5.94	38.5	12.6	64.9	32.7
CanL 5		5.01	35.0	11.8	69.9	33.7
CanL 6		2.49	16.7	5.2	67.1	31.1
CanL 7		2.37	18.5	6.0	78.1	32.4
CanL 8		3.74	17.0	8.5	64.2	35.4
CanL 9		3.62	19.9	7.2	55.1	36.1
CanL 10		4.30	28.8	10.0	67.0	34.7
	Mean±SD	**3.85±1.08[a]**	**24.8±7.4[a]**	**8.4±2.4[a]**	**66.8±7.0[a]**	**32.7±2.3[a]**
Control 1		8.26	55.0	18.1	66.5	32.7
Control 2		7.21	53.8	18.8	74.7	34.9
Control 3		5.32	41.2	12.9	77.5	31.3
Control 4		7.43	52.7	15.4	76.4	35.9
Control 5		7.96	53.9	16.8	75.3	34.7
	Mean±SD	**7.24±1.15[b]**	**51.3±5.7[b]**	**16.4±2.3[b]**	**74.1±4.4[a]**	**33.9±1.9[a]**

CanL: canine leishmaniasis. Control: healthy negative control. RBC: red blood cells, Ht: hematocrit, MCHC: mean corpuscular hemoglobin concentration, MCV: mean corpuscular volume. a,b Equal letters in the same colum indicate no statistical difference using unpaired t-test

Table S4. White blood cells and platelets counts.

Dog #		Leukocytes	Neutrophils	Lymphocytes	Monocytes	Eosinophils	Basophils	Platelets
	Ref. values	**6-17 x10³/ µL**	**3,000-11,000/µL**	**1,000-4,800/µL**	**150-1,350/µL**	**150-1,250/µL**	**Rares/ µL**	**160-430 x10³/µL**
CanL 1		9.8	6.272	2.156	392	980	0	145
CanL 2		23.9	13.076	2.760	478	478	0	165
CanL 3		10.2	7.752	1.836	510	102	0	82
CanL 4		6.3	4.158	1.071	756	63	0	159
CanL 5		12.5	9.500	1.375	1.125	500	0	420
CanL 6		14.9	9.238	3.427	1.043	1.192	0	277
CanL 7		12.5	10.000	1.750	375	375	0	331
CanL 8		14.8	6.808	5.032	2.220	740	0	168
CanL 9		8.7	6.264	2.001	174	261	0	95
CanL 10		11.8	10.738	0.708	354	200	0	60
	Mean± SD	**12.5± 4.8[a]**	**8.381± 2.621[a]**	**2.212± 1.265[a]**	**743± 603[a]**	**489± 377[a]**	**0±0[a]**	**190± 116[a]**
Control 1		10.2	6.324	3.468	102	306	0	341
Control 2		8.8	6.160	1.408	880	352	0	296
Control 3		13.1	6.419	6.668	174	261	0	341
Control 4		8.4	4.480	1.024	512	384	0	211
Control 5		10.6	7.844	1.060	424	1.250	0	228
	Mean± SD	**10.2± 1.9a**	**6.245± 1.195a**	**2.726± 2.424[a]**	**418± 309[a]**	**261± 152[a]**	**0±0[a]**	**283± 61[a]**

CanL: canine leishmaniasis. Control: healthy negative control. a,b Equal letters in the same colum indicate no statistical difference using unpaired t-test

REFERÊNCIAS DA INTRODUÇÃO GERAL

1. WHO. Control of the leishmaniases. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases. **WHO Technical Report Series 949**. Geneve, Switzerland; 2010. p. 202. Disponível em: https://apps.who.int/iris/bitstream/handle/10665/44412/WHO_TRS_949_eng.pdf;jsessionid=8D39FF652FD5A79349D7621163D2F3BF?sequence=1

2. WHO. Leishmaniasis. In: **WHO World Health Organization [Internet]**. 2018 [Acesso em 1 Feb 2019]. Disponível em: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis

3. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. **Lancet**. 2005;366: 1561–1577. doi:10.1016/S0140-6736(05)67629-5

4. WHO. Investing to overcome the global impact of neglected tropical diseases. In: **World Health Organization [Internet]**. 2015 [Acesso em 21 Jan 2019]. Disponível em:: https://www.who.int/neglected_diseases/9789241564861/en/

5. Ministério da Saúde (BR)**. Leishmaniose Visceral - Situação Epidemiológica - Dados [Internet]**. 2019 [cited 20 Jan 2019]. Available: http://portalms.saude.gov.br/saude-de-a-z/leishmaniose-visceral/11334-situacao-epidemiologica-dados

6. Secretária de Estado da Saúde (SP). **Leishmaniose Visceral [Internet]**. 2019 [Acesso em 26 Mar 2019]. Available: http://www.saude.sp.gov.br/cve-centro-de-vigilancia-epidemiologica-prof.-alexandre-vranjac/areas-de-vigilancia/doencas-de-transmissao-por-vetores-e-zoonoses/agravos/leishmaniose-visceral/

7. Feitosa MM, Ikeda FA, Luvizzoto MCR PS. Aspectos clínicos de cães com leishmaniose visceral no município de Araçatuba–São Paulo (Brasil). **Clínica Veterinária**. 2000;28: 36–44.

8. Cardim MFM, Guirado MM, Dibo MR, Chiaravalloti Neto F. Visceral leishmaniasis in the state of Sao Paulo, Brazil: spatial and space-time analysis. **Rev Saude Publica**. 2016;50. doi:10.1590/S1518-8787.2016050005965

9. Alencar, J. E.; Dietze R**. Leishmaniose Visceral (Calazar)**. In: VERONESI, R. Doenças infecciosas e parasitárias. 8th ed. Rio de Janeiro: Guanabara Koogan; 1991.

10. de Pita-Pereira D, Cardoso MAB, Alves CR, Brazil RP, Britto C. Detection of natural infection in *Lutzomyia cruzi* and *Lutzomyia forattinii* (Diptera: Psychodidae: Phlebotominae) by *Leishmania infantum chagasi* in an endemic area of visceral leishmaniasis in Brazil using a PCR multiplex assay. **Acta Trop**. 2008;107: 66–69. doi:10.1016/j.actatropica.2008.04.015

11. Dantas-Torres F. Canine leishmaniosis in South America. **Parasit Vectors.** 2009;2: S1. doi:10.1186/1756-3305-2-S1-S1

12. Otranto D, Dantas-Torres F. Fleas and ticks as vectors of *Leishmania spp*. to dogs: Caution is needed. **Vet Parasitol**. 2010;168: 173–174. doi:10.1016/j.vetpar.2009.11.016

13. Dantas-Torres F. Ticks as vectors of Leishmania parasites. **Trends Parasitol**. 2011;27: 155–159. doi:10.1016/j.pt.2010.12.006

14. Silva FL, Oliveira RG, Silva TMA, Xavier MN, Nascimento EF, Santos RL. Venereal transmission of canine visceral leishmaniasis. **Vet Parasitol**. 2009;160: 55–59. doi:10.1016/j.vetpar.2008.10.079

15. Boggiatto PM, Gibson-Corley KN, Metz K, Gallup JM, Hostetter JM, Mullin K, et al. Transplacental Transmission of *Leishmania infantum* as a Means for Continued Disease Incidence in North America. Boelaert M, editor. **PLoS Negl Trop Dis**. 2011;5: e1019. doi:10.1371/journal.pntd.0001019

16. Pangrazio KK, Costa EA, Amarilla SP, Cino AG, Silva TMA, Paixão TA, et al.

Tissue distribution of *Leishmania chagasi* and lesions in transplacentally infected fetuses from symptomatic and asymptomatic naturally infected bitches. **Vet Parasitol**. 2009;165: 327–331. doi:10.1016/j.vetpar.2009.07.013

17. Rosypal AC, Lindsay DS. Non-sand fly transmission of a north american isolate of *leishmania infantum* in experimentally infected balb/c mice. **J Parasitol**. 2005;91: 1113–1115. doi:10.1645/GE-586R.1

18. Owens SD, Oakley DA, Marryott K, Hatchett W, Walton R, Nolan TJ, et al. Transmission of visceral leishmaniasis through blood transfusions from infected English foxhounds to anemic dogs. **J Am Vet Med Assoc**. 2001;219: 1076–83. Available: http://www.ncbi.nlm.nih.gov/pubmed/11700704

19. Moreno J, Alvar J. Canine leishmaniasis : epidemiological risk and the experimental model. **Trends Parasitol**. 2002;18: 399–405.

20. Teixeira-Neto RG, da Silva ES, Nascimento RA, Belo VS, de Oliveira C di L, Pinheiro LC, et al. Canine visceral leishmaniasis in an urban setting of Southeastern Brazil: an ecological study involving spatial analysis. **Parasit Vectors**. 2014;7: 485. doi:10.1186/s13071-014-0485-7

21. Costa DNCC, Bermudi PMMB, Rodas LAC, Nunes CM, Hiramoto RM, Tolezano JE, et al. Human visceral leishmaniasis and relationship with vector and canine control measures. **Rev Saude Publica**. 2018;52: 92. doi:10.11606/S1518-8787.2018052000381

22. Silva FM de F, Santos EM de S, Torres SM, Yamasak EM, Ramos RAN, Alves LC. Parasite load in intact and ulcerative skin of dogs with leishmaniais. **Rev Bras Parasitol Veterinária**. 2016;25: 127–130. doi:10.1590/S1984-29612016014

23. Baneth G, Koutinas AF, Solano-Gallego L, Bourdeau P, Ferrer L. Canine leishmaniosis – new concepts and insights on an expanding zoonosis: part one. **Trends Parasitol**. 2008;24: 324–330. doi:10.1016/j.pt.2008.04.001

24. Ribeiro RR, Michalick MSM, da Silva ME, dos Santos CCP, Frézard FJG, da Silva SM. Canine Leishmaniasis: An Overview of the Current Status and Strategies for Control. **Biomed Res Int**. 2018;2018: 1–12. doi:10.1155/2018/3296893

25. Alvar J, Cañavate C, Molina R, Moreno J, Nieto J. Canine leishmaniasis. **Adv Parasitol**. 2004;57: 1–88. doi:10.1016/S0065-308X(04)57001-X

26. Thalhofer CJ, Chen Y, Sudan B, Love-Homan L, Wilson ME. Leukocytes infiltrate the skin and draining lymph nodes in response to the protozoan *leishmania infantum chagasi*. **Infect Immun**. 2011;79: 108–117. doi:10.1128/IAI.00338-10

27. Rittig MG, Bogdan C. Leishmania-host-cell interaction: Complexities and alternative views. **Parasitol Today**. 2000;16: 292–297. doi:10.1016/S0169-4758(00)01692-6

28. Papadogiannakis EI, Koutinas AF. Cutaneous immune mechanisms in canine leishmaniosis due to *Leishmania infantum*. **Vet Immunol Immunopathol**. 2015;163: 94–102. doi:10.1016/j.vetimm.2014.11.011

29. Hosein S, Blake DP, Solano-Gallego L. Insights on adaptive and innate immunity in canine leishmaniosis. **Parasitology**. 2017;144: 95–115. doi:10.1017/S003118201600055X

30. Lasser A. The mononuclear phagocytic system: a review. **Hum Pathol**. 1983;14: 108–26. Available: http://www.ncbi.nlm.nih.gov/pubmed/6339357

31. Bogdan C, Röllinghoff M. The immune response to Leishmania: mechanisms of parasite control and evasion. **Int J Parasitol**. 1998;28: 121–34. Available: http://www.ncbi.nlm.nih.gov/pubmed/9504340

32. Santana CC, Vassallo J, De Freitas LAR, Oliveira GGS, Pontes-De-Carvalho LC, Dos-Santos WLC. Inflammation and structural changes of splenic lymphoid

tissue in visceral leishmaniasis: A study on naturally infected dogs. **Parasite Immunol**. 2008;30: 515–524. doi:10.1111/j.1365-3024.2008.01051.x

33. Koutinas AF, Koutinas CK. Pathologic Mechanisms Underlying the Clinical Findings in Canine Leishmaniosis due to *Leishmaniainfantum/chagasi*. **Vet Pathol**. 2014;51: 527–538. doi:10.1177/0300985814521248

34. Solano-Gallego L, Miró G, Koutinas A, Cardoso L, Pennisi M, Ferrer L, et al. LeishVet guidelines for the practical management of canine leishmaniosis. **Parasit Vectors**. 2011;4: 86. doi:10.1186/1756-3305-4-86

35. Mir F, Fontaine E, Reyes-Gomez E, Carlus M, Fontbonne A. Subclinical leishmaniasis associated with infertility and chronic prostatitis in a dog. **J Small Anim Pract**. 2012;53: 419–422. doi:10.1111/j.1748-5827.2012.01224.x

36. Diniz SA, Silva FL, Carvalho Neta AC, Bueno R, Guerra RMSNC, Abreu-Silva AL, et al. Animal reservoirs for visceral leishmaniasis in densely populated urban areas. **J Infect Dev Ctries**. 2008;2: 24–33. Available: http://www.ncbi.nlm.nih.gov/pubmed/19736384

37. Santos-Gomes GM, Rosa R, Leandro C, Cortes S, Romão P, Silveira H. Cytokine expression during the outcome of canine experimental infection by *Leishmania infantum*. **Vet Immunol Immunopathol**. 2002;88: 21–30. doi:10.1016/S0165-2427(02)00134-4

38. Barbiéri CL. Immunology of canine leishmaniasis. **Parasite Immunol**. 2006;28: 329–337. doi:10.1111/j.1365-3024.2006.00840.x

39. Mendes-Sousa AF, Nascimento AAS, Queiroz DC, Vale VF, Fujiwara RT, Araújo RN, et al. Different Host Complement Systems and Their Interactions with Saliva from *Lutzomyia longipalpis* (Diptera, Psychodidae) and *Leishmania infantum* Promastigotes. Sturtevant J, editor. **PLoS One**. 2013;8: e79787. doi:10.1371/journal.pone.0079787

40. Zamboni DS, Lima-Junior DS. Inflammasomes in host response to protozoan parasites. **Immunol Rev**. 2015;265: 156–171. doi:10.1111/imr.12291

41. Becker I, Salaiza N, Aguirre M, Delgado J, Carrillo-Carrasco N, Kobeh LG, et al. Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2. **Mol Biochem Parasitol**. 2003;130: 65–74. Available: http://www.ncbi.nlm.nih.gov/pubmed/12946842

42. Carrada G, Cañeda C, Salaiza N, Delgado J, Ruiz AS, Gutiérrez-Kobehg L, et al. Monocyte cytokine and costimulatory molecule expression in patients infected with *Leishmania mexicana*. **Parasite Immunol**. 2007;29: 117–126. doi:10.1111/j.1365-3024.2006.00924.x

43. Faria MS, Reis FCG, Lima APCA. Toll-Like Receptors in Leishmania Infections: Guardians or Promoters? **J Parasitol Res**. 2012;2012: 1–12. doi:10.1155/2012/930257

44. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. molecular mechanisms regulating th1 immune responses. **Annu Rev Immunol**. 2003; 21:713-758. doi:10.1146/annurev.immunol.21.120601.140942

45. Ribeiro-Gomes FL, Peters NC, Debrabant A, Sacks DL. Efficient capture of infected neutrophils by dendritic cells in the skin inhibits the early anti-leishmania response. **PLoS Pathog**. 2012;8. doi:10.1371/journal.ppat.1002536

46. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. **Nat Immunol**. 2000; 4:311-316. doi: 10.1038/79758

47. Pinelli E, Rutten VPMG, Bruysters M, Moore PF, Ruitenberg EJ. Compensation for decreased expression of B7 molecules on *Leishmania infantum*-infected canine macrophages results in restoration of parasite- specific T-cell proliferation and gamma interferon production. **Infect Immun**. 1999;67: 237–243.

48. Kaye PM, Svensson M, Ato M, Maroof A, Polley R, Stager S, et al. The immunopathology of experimental visceral leishmaniasis. **Immunol Rev**. 2004;201: 239–253. doi:10.1111/j.0105-2896.2004.00188.x

49. Murray HW, Cartelli DM. Killing of intracellular *Leishmania donovani* by human mononuclear phagocytes. Evidence for oxygen-dependent and -independent leishmanicidal activity**. J Clin Invest**. 1983;72: 32–44. doi:10.1172/JCI110972

50. Panaro MA, Fasanella A, Lisi S, Mitolo V, Andriola A, Brandonisio O. Evaluation of Nitric Oxide Production by *Leishmania Infantum*-infected Dog Macrophages. **Immunopharmacol Immunotoxicol**. 1998;20: 147–158. doi:10.3109/08923979809034814

51. Gradoni L. An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine. **Vet Parasitol**. 2001;100: 87–103. doi:10.1016/S0304-4017(01)00486-1

52. Cardoso L, Schallig HDFH, Cordeiro-da-Silva A, Cabral M, Alunda JM, Rodrigues M. Anti-Leishmania humoral and cellular immune responses in naturally infected symptomatic and asymptomatic dogs. **Vet Immunol Immunopathol**. 2007;117: 35–41. doi:10.1016/j.vetimm.2007.01.014

53. Solano-gallego L, Montserrrat-sangrà S, Ordeix L, Martínez-orellana P. Leishmania infantum -specific production of IFN- γ and IL-10 in stimulated blood from dogs with clinical leishmaniosis. **Parasit Vectors**. 2016; 1–10. doi:10.1186/s13071-016-1598-y

54. Alves CF, de Amorim IFG, Moura EP, Ribeiro RR, Alves CF, Michalick MS, et al. Expression of IFN-γ, TNF-α, IL-10 and TGF-β in lymph nodes associates with parasite load and clinical form of disease in dogs naturally infected with *Leishmania (Leishmania) chagasi*. **Vet Immunol Immunopathol**. 2009;128: 349–358. doi:10.1016/j.vetimm.2008.11.020

55. Boggiatto PM, Ramer-Tait AE, Metz K, Kramer EE, Gibson-Corley K, Mullin K,

et al. Immunologic indicators of clinical progression during canine Leishmania infantum infection. **Clin Vaccine Immunol**. 2010;17: 267–273. doi:10.1128/CVI.00456-09

56. Nascimento PRP do, Martins DRA, Monteiro GRG, Queiroz PV, Freire-Neto FP, Queiroz JW, et al. Association of Pro-Inflammatory Cytokines and Iron Regulatory Protein 2 (IRP2) with Leishmania Burden in Canine Visceral Leishmaniasis. **PLoS One**. 2013;8: 1–10. doi:10.1371/journal.pone.0073873

57. Aslan H, Oliveira F, Meneses C, Castrovinci P, Gomes R, Teixeira C, et al. New insights into the transmissibility of *leishmania infantum* from dogs to sand flies: Experimental vector-transmission reveals persistent parasite depots at bite sites. **J Infect Dis**. 2016;213: 1752–1761. doi:10.1093/infdis/jiw022

58. O’Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C. Strategies for use of IL-10 or its antagonists in human disease. **Immunol Rev**. 2008;223: 114–131. doi:10.1111/j.1600-065X.2008.00635.x

59. Schaut RG, Lamb IM, Toepp AJ, Scott B, Mendes-Aguiar CO, Coutinho JF V., et al. Regulatory IgD hi B Cells Suppress T Cell Function via IL-10 and PD-L1 during Progressive Visceral Leishmaniasis. **J Immunol**. 2016;196: 4100–4109. doi:10.4049/jimmunol.1502678

60. Day MJ. Immunoglobulin G subclass distribution in canine leishmaniosis: A review and analysis of pitfalls in interpretation. **Vet Parasitol**. 2007;147: 2–8. doi:10.1016/j.vetpar.2007.03.037

61. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. **Nat Immunol**. 2007;8: 239–245. doi:10.1038/ni1443

62. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. **Nat Rev Cancer**. 2012;12: 252–264. doi:10.1038/nrc3239

63. Esch KJ, Juelsgaard R, Martinez PA, Jones DE, Christine A. PD-1-mediated T cell exhaustion during visceral leishmaniasis impairs phagocyte function Kevin. **J Immunol**. 2013;191: 5542–5550. doi:10.4049/jimmunol.1301810.PD-1-mediated

64. Chiku VM, Silva KLO, de Almeida BFM, Venturin GL, Leal AAC, de Martini CC, et al. PD-1 function in apoptosis of T lymphocytes in canine visceral leishmaniasis**. Immunobiology**. 2016;221: 879–888. doi:10.1016/j.imbio.2016.03.007

65. Oliveira Silva KL, Marin Chiku V, Luvizotto Venturin G, Correa Leal AA, de Almeida BF, De Rezende Eugenio F, et al. PD-1 and PD-L1 regulate cellular immunity in canine visceral leishmaniasis. **Comp Immunol Microbiol Infect Dis**. 2019;62: 76–87. doi:10.1016/j.cimid.2018.12.002

66. Bacellar O, Brodskyn C, Guerreiro J, Barral-Netto M, Costa CH, Coffman RL, et al. Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis. **J Infect Dis**. 1996;173: 1515–8. doi:10.1093/infdis/173.6.1515

67. D’Oliveira Júnior A, Costa SRM, Bispo Barbosa A, Orge Orge M de LG, Carvalho EM. Asymptomatic *Leishmania chagasi* Infection in Relatives and Neighbors of Patients with Visceral Leishmaniasis. **Mem Inst Oswaldo Cruz**. 1997;92: 15–20. doi:10.1590/S0074-02761997000100003

68. Pinelli E, Wagenaar J, Bernadina W, Pinelli E, Killick-kendrick R, Wagenaar J, et al. Cellular and Humoral Immune Responses in Dogs Experimentally and Naturally Infected with *Leishmania infantum*. **Infect Immun**. 1994;62: 229–235(7). doi:0019-9567/94/$04.00+0

69. Pinelli E, Gonzalo RM, Boog CJP, Rutten VPMG, Gebhard D, Del Real G, et al. *Leishmania infantum*-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocompatibility complex-restricted manner**. Eur J Immunol**. 1995;25: 1594–1600. doi:10.1002/eji.1830250619

70. Strauss-Ayali D, Baneth G, Shor S, Okano F, Jaffe CL. Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in *Leishmania infantum*-infected dogs. **Int J Parasitol**. 2005;35: 63–73. doi:10.1016/j.ijpara.2004.10.015

71. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. **Nat Rev Immunol**. 2012;12: 180–190. doi:10.1038/nri3156

72. Hatakeyama M, Tsudo M, Minamoto S, Kono T, Doi T, Miyata T, et al. Interleukin-2 receptor β chain gene: Generation of three receptor forms by cloned human α and β chain cDNA's. **Science**. 1989;244: 551–556. doi:10.1126/science.2785715

73. Carvalho EM, Bacellar O, Brownell C, Regis T, Coffman RL, Reed SG. Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. **J immunol**. 1994;152: 5949–56. Available: http://www.ncbi.nlm.nih.gov/pubmed/8207220

74. Fehniger TA, Caligiuri M. Interleukin 15 : biology and relevance to human disease**. Blood**. 2001;97: 14–32. doi:10.1182/blood.V97.1.14

75. Geginat J, Sallusto F, Lanzavecchia A. Cytokine-driven Proliferation and Differentiation of Human Naive, Central Memory, and Effector Memory CD4 . **Pathol Biol**. 2003; 51:64-66 doi:10.1084/jem.194.12.1711

76. Cieri N, Camisa B, Cocchiarella F, Forcato M, Oliveira G, Provasi E, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. **Blood**. 2013;121: 573–584. doi:10.1182/blood-2012-05-431718

77. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. **J Exp Med**. 1994;180: 1395–403. Available: http://www.ncbi.nlm.nih.gov/pubmed/7523571

78. Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in nk cell differentiation and host response to intracellular pathogens. **Annu Rev Immunol**. 1999;17: 19–49. doi:10.1146/annurev.immunol.17.1.19

79. Takeuchi E, Yanagawa H, Suzuki Y, Shinkawa K, Bando H, Sone S. Interleukin (IL-)15 has less activity than IL-2 to promote type 2 cytokine predominance in tumour-associated mononuclear cells from lung cancer patients. **Cytokine**. 2001;13: 119–123. doi:10.1006/cyto.2000.0808

80. Milano S, Di Bella G, D'Agostino P, Barbera C, Caruso R, La Rosa M, et al. IL-15 in human visceral leishmaniasis caused by *Leishmania infantum*. **Clin Exp Immunol**. 2002;127: 360–365. doi:10.1046/j.1365-2249.2002.01749.x

81. Hsieh C, Macatonia SE, Tripp CS, Wolf SF, Garra AO, Murphy KM. Pillars Article : Development of TH1 CD4 + T Cells Through IL-12 Produced by Listeria. **J Immunol**. 2013;181: 4437–9.

82. dos Santos LR, Barrouin-Melo SM, Chang Y-F, Olsen J, McDonough SP, Quimby F, et al. Recombinant single-chain canine interleukin 12 induces interferon gamma mRNA expression in peripheral blood mononuclear cells of dogs with visceral leishmaniasis. **Vet Immunol Immunopathol**. 2004;98: 43–48. doi:10.1016/j.vetimm.2003.10.006

83. ElKassar N, Gress RE. An overview of IL-7 biology and its use in immunotherapy. **J Immunotoxicol**. 2010;7: 1–7. doi:10.3109/15476910903453296

84. Gessner A, Vieth M, Will A, Schröppel K, Röllinghoff M. Interleukin-7 enhances antimicrobial activity against Leishmania major in murine macrophages. **Infect Immun**. 1993;61: 4008–12. Available: http://www.ncbi.nlm.nih.gov/pubmed/8359927

85. Pereira AM, De Pinheiro CGM, Dos Santos LR, Teixeira NC, Chang YF,

Pontes-De-Carvalho LC, et al. Requirement of dual stimulation by homologous recombinant IL-2 and recombinant IL-12 for the in vitro production of interferon gamma by canine peripheral blood mononuclear cells. **BMC Res Notes**. 2014;7: 1–10. doi:10.1186/1756-0500-7-460

86. Yoshikai Y, Nishimura H. The role of interleukin 15 in mounting an immune response against microbial infections. **Microbes Infect**. 2000;2: 381–389. doi:10.1016/S1286-4579(00)00329-4

87. Reguera RM, Morán M, Pérez-Pertejo Y, García-Estrada C, Balaña-Fouce R. Current status on prevention and treatment of canine leishmaniasis. **Vet Parasitol**. 2016;227: 98–114. doi:10.1016/j.vetpar.2016.07.011

88. dos Santos Nogueira F, Avino VC, Galvis-Ovallos F, Pereira-Chioccola VL, Moreira MAB, Romariz APPL, et al. Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil. **Parasit Vectors**. 2019;12: 79. doi:10.1186/s13071-019-3323-0

ANEXO

ANEXO A - NORMAS PARA PUBLICAÇÃO NA REVISTA PLOS NEGLECTED TROPICAL DISEASE

Submission Guidelines
PLOS Neglected Tropical Diseases publishes original research articles of importance to the NTDs community and the wider health community. We will consider manuscripts of any length; we encourage the submission of both substantial full-length bodies of work and shorter manuscripts that report novel findings that might be based on a more limited range of experiments.
The writing style should be concise and accessible, avoiding jargon so that the paper is understandable for readers outside a specialty or those whose first language is not English. Editors will make suggestions for how to achieve this, as well as suggestions for cuts or additions that could be made to the article to strengthen the argument. Our aim is to make the editorial process rigorous and consistent, but not intrusive or overbearing. Authors are encouraged to use their own voice and to decide how best to present their ideas, results, and conclusions.
PLOS Neglected Tropical Diseases is committed to the highest ethical standards in medical research. Accordingly, we ask authors to provide specific information regarding ethical treatment of research participants, patient consent, patient privacy, protocols, authorship, and competing interests. We also ask that reports of certain specific types of studies adhere to generally accepted standards. Our requirements are based on the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, issued by the International Committee for Medical Journal Editors.

Style and Format

Manuscript Organization
Most manuscripts should be organized as follows. Instructions for each element appear below.

- Title
- Authors and Affiliations
- Abstract
- Author Summary
- Introduction
- Methods
- Results
- Discussion
- Acknowledgments
- References
- Supporting information Captions

Uniformity in format facilitates the experience of readers and users of the journal. To provide flexibility, however, the Results and Discussion can be combined into one Results/Discussion section.
Other elements

- Figure captions are inserted immediately after the first paragraph in which the figure is cited. Figure files are uploaded separately.
- Tables are inserted immediately after the first paragraph in which they are cited.
- Supporting information files are uploaded separately.

The compiled submission PDF includes low-resolution preview images of the figures after the reference list. The function of these previews is to allow you to download the entire submission as quickly as possible. Click the link at the top of each preview page to download a high-resolution version of each figure. Links to download Supporting Information files are also available after the reference list.
Parts of a Submission

Title
Include a full title and a short title for the manuscript.

Titles should be written in sentence case (only the first word of the text, proper nouns, and genus names are capitalized). Avoid specialist abbreviations if possible. For clinical trials, systematic reviews, or meta-analyses, the subtitle should include the study design.

Author names and affiliations
Enter author names on the title page of the manuscript and in the online submission system.
On the title page, write author names in the following order:

- First name (or initials, if used)
- Middle name (or initials, if used)
- Last name (surname, family name)

Each author on the list must have an affiliation. The affiliation includes department, university, or organizational affiliation and its location, including city, state/province (if applicable), and country. Authors have the option to include a current address in addition to the address of their affiliation at the time of the study. The current address should be listed in the byline and clearly labeled "current address." At a minimum, the address must include the author's current institution, city, and country.
If an author has multiple affiliations, enter all affiliations on the title page only. In the submission system, enter only the preferred or primary affiliation. Author affiliations will be listed in the typeset PDF article in the same order that authors are listed in the submission.

Corresponding author
The submitting author is automatically designated as the corresponding author in the submission system. The corresponding author is the primary contact for the journal office and the only author able to view or change the manuscript while it is under editorial consideration.
The corresponding author role may be transferred to another coauthor. However, note that transferring the corresponding author role also transfers access to the manuscript. (To designate a new corresponding author while the manuscript is still under consideration, watch the video tutorial below.)
Only one corresponding author can be designated in the submission system, but this does not restrict the number of corresponding authors that may be listed on the article in the event of publication. Whoever is designated as a corresponding author on the title page of the manuscript file will be listed as such upon publication. Include an email address for each corresponding author listed on the title page of the manuscript.

Consortia and group authorship
If a manuscript is submitted on behalf of a consortium or group, include its name in the manuscript byline. Do not add it to the author list in the submission system. You may include the full list of members in the Acknowledgments or in a supporting information file.
PubMed only indexes individual consortium or group author members listed in the article byline. If included, these individuals must qualify for authorship according to our criteria.

Author contributions
Provide at minimum one contribution for each author in the submission system. Use the CRediT taxonomy to describe each contribution. Read the policy and the full list of roles.
Contributions will be published with the final article, and they should accurately reflect contributions to the work. The submitting author is responsible for completing this information at submission, and we expect that all authors will have reviewed, discussed, and agreed to their individual contributions ahead of this time.

Cover letter
Upload a cover letter as a separate file in the online system.
The cover letter should address the following questions:

- Why is this manuscript suitable for publication in *PLOS Neglected Tropical Diseases*?
- Why will your study inspire the NTDs community, and how will it drive the understanding of NTD pathobiology, epidemiology, prevention, treatment, control, or policy?

If your study addresses an infection that is outside our detailed scope, you must first send a presubmission inquiry indicating why you consider the infection to be a neglected tropical disease.
The cover letter will be available to the editors and to any external peer reviewers, so please send anything confidential directly to the journal office.

Title page
The title, authors, and affiliations should all be included on a title page as the first page of the manuscript file.

Abstract
The Abstract comes after the title page in the manuscript file. The abstract text is also entered in a separate field in the submission system.
The Abstract succinctly introduces the paper. It should not exceed 250–300 words. It should mention the techniques used without going into methodological detail and summarize the most important results with important numerical results given.
The Abstract is conceptually divided into the following three sections with these headings: Background, Methodology/Principal Findings, and Conclusions/Significance.
Do not include any citations in the Abstract. Avoid specialist abbreviations.

Author Summary
We ask that all authors of research articles include a 150- to 200-word non-technical summary of the work, immediately following the Abstract. Subject to editorial review and author revision, this short text is published with all research articles as a highlighted text box.

Distinct from the scientific abstract, the Author Summary should highlight where the work fits in a broader context of life science knowledge and why these findings are important to an audience that includes both scientists and non-scientists. Ideally aimed to a level of understanding of an undergraduate student, the significance of the work should be presented simply, objectively, and without exaggeration.
Authors should avoid the use of acronyms and complex scientific terms and write the author summary using the first-person voice. Authors may benefit from consulting with a science writer or press officer to ensure that they effectively communicate their findings to a general audience.

Introduction
The Introduction should put the focus of the manuscript into a broader context. As you compose the Introduction, think of readers who are not experts in this field. Include a brief review of the key literature. If there are relevant controversies or disagreements in the field, they should be mentioned so that a non-expert reader can delve into these issues further. The Introduction should conclude with a brief statement of the overall aim of the experiments and a comment about whether that aim was achieved.

Methods
This section should provide enough detail for reproduction of the findings. Protocols for new methods should be included, but well-established protocols may simply be referenced. Detailed methodology or supporting information relevant to the methodology can be published on our web site.
This section should also include a section with descriptions of any statistical methods employed. These should conform to the criteria outlined by the Uniform Requirements, as follows:
Submit detailed protocols for newer or less established methods. Well-established protocols may simply be referenced. Protocol documents for clinical trials, observational studies, and other **non-laboratory** investigations may be uploaded as supporting information.
We recommend and encourage you to deposit **laboratory protocols** in protocols.io, where protocols can be assigned their own persistent digital object identifiers (DOIs).
To include a link to a protocol in your article:

1. Describe your step-by-step protocol on protocols.io
2. Select **Get DOI** to issue your protocol a persistent digital object identifier (DOI)
3. Include the DOI link in the Methods section of your manuscript using the following format provided by protocols.io: http://dx.doi.org/10.17504/protocols.io.[PROTOCOL DOI]

At this stage, your protocol is only visible to those with the link. This allows editors and reviewers to consult your protocol when evaluating the manuscript. You can make your protocols public at any time by selecting **Publish** on the protocols.io site. Any referenced protocol(s) will automatically be made public when your article is published.

Results
The Results section should include all relevant positive and negative findings. The section may be divided into subsections, each with a concise subheading. The Results section should be written in past tense.
PLOS journals require authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception.
Large data sets, including raw data, may be deposited in an appropriate public repository. See our list of recommended repositories.
For smaller data sets and certain data types, authors may provide their data within supporting information files accompanying the manuscript. Authors should take care to maximize the accessibility and reusability of the data by selecting a file format from which data can be efficiently extracted (for example, spreadsheets or flat files should be provided rather than PDFs when providing tabulated data).
For more information on how best to provide data, read our policy on data availability. PLOS does not accept references to "data not shown."
As outlined in the Uniform Requirements, authors that present statistical data in the Results section should do the following:

Discussion
The Discussion should be concise and tightly argued. It should start with a brief summary of the main findings. It should include paragraphs on the generalizability, clinical relevance, strengths, and limitations of your study.
You may wish to discuss the following points also:

- How do the conclusions affect the existing knowledge in the field?
- How can future research build on these observations and what are the key experiments that must be done?

Acknowledgments
Those who contributed to the work but do not meet our authorship criteria should be listed in the Acknowledgments with a description of the contribution.
Authors are responsible for ensuring that anyone named in the Acknowledgments agrees to be named.

References
Any and all available works can be cited in the reference list. Acceptable sources include:

- Published or accepted manuscripts

- Manuscripts on preprint servers, providing the manuscript has a citable DOI or arXiv URL.

Do not cite the following sources in the reference list:

- Unavailable and unpublished work, including manuscripts that have been submitted but not yet accepted (e.g., “unpublished work,” “data not shown”). Instead, include those data as supplementary material or deposit the data in a publicly available database.
- Personal communications (these should be supported by a letter from the relevant authors but not included in the reference list)

References are listed at the end of the manuscript and numbered in the order that they appear in the text. In the text, cite the reference number in square brackets (e.g., “We used the techniques developed by our colleagues [19] to analyze the data”). PLOS uses the numbered citation (citation-sequence) method and first six authors, et al.
Do not include citations in abstracts.
Make sure the parts of the manuscript are in the correct order *before* ordering the citations.

Formatting references
PLOS uses the reference style outlined by the International Committee of Medical Journal Editors (ICMJE), also referred to as the “Vancouver” style. Example formats are listed below. Additional examples are in the ICMJE sample references.
Journal name abbreviations should be those found in the National Center for Biotechnology Information (NCBI) databases.

Supporting Information
Authors can submit essential supporting files and multimedia files along with their manuscripts. All supporting information will be subject to peer review. All file types can be submitted, but files must be smaller than 10 MB in size.
Authors may use almost any description as the item name for a supporting information file as long as it contains an “S” and number. For example, “S1 Appendix” and “S2 Appendix,” “S1 Table” and “S2 Table,” and so forth.
Supporting information files are published exactly as provided, and are not copyedited.
Supporting information captions
List supporting information captions at the end of the manuscript file. Do not submit captions in a separate file.
The file number and name are required in a caption, and we highly recommend including a one-line title as well. You may also include a legend in your caption, but it is not required.

In-text citations
We recommend that you cite supporting information in the manuscript text, but this is not a requirement. If you cite supporting information in the text, citations do not need to be in numerical order.

Figures and Tables
Figures
You can include figures in the main manuscript file at initial submission. If the manuscript reaches the revise stage, prepare and submit each figure as an individual file.
Cite figures in ascending numeric order at first appearance in the manuscript file.

Figure captions
Insert figure captions in manuscript text, immediately following the paragraph where the figure is first cited (read order). Don’t include captions as part of the figure files themselves or submit them in a separate document.
At a minimum, include the following in your figure captions:

- A figure label with Arabic numerals, and “Figure” abbreviated to “Fig” (e.g. Fig 1, Fig 2, Fig 3, etc). Match the label of your figure with the name of the file uploaded at submission (e.g. a figure citation of “Fig 1” must refer to a figure file named “Fig1.tif”).
- A concise, descriptive title

The caption may also include a legend as needed.

Tables
Cite tables in ascending numeric order upon first appearance in the manuscript file.
Place each table in your manuscript file directly after the paragraph in which it is first cited (read order). Do not submit your tables in separate files.
Tables require a label (e.g., “Table 1”) and brief descriptive title to be placed above the table. Place legends, footnotes, and other text below the table.

Data reporting
All data and related metadata underlying the findings reported in a submitted manuscript should be deposited in an appropriate public repository, unless already provided as part of the submitted article.
Repositories may be either subject-specific (where these exist) and accept specific types of structured data, or generalist repositories that accept multiple data types. We recommend that authors select repositories appropriate to their field. Repositories may be subject-specific (e.g., GenBank for sequences and PDB for

structures), general, or institutional, as long as DOIs or accession numbers are provided and the data are at least as open as CC BY. Authors are encouraged to select repositories that meet accepted criteria as trustworthy digital repositories, such as criteria of the Centre for Research Libraries or Data Seal of Approval. Large, international databases are more likely to persist than small, local ones.

To support data sharing and author compliance of the PLOS data policy, we have integrated our submission process with a select set of data repositories. The list is neither representative nor exhaustive of the suitable repositories available to authors. Current repository integration partners include Dryad and FlowRepository. Please contact data@plos.org to make recommendations for further partnerships.
Instructions for PLOS submissions with data deposited in an integration partner repository:

- Deposit data in the integrated repository of choice.
- Once deposition is final and complete, the repository will provide you with a dataset DOI (provisional) and private URL for reviewers to gain access to the data.
- Enter the given data DOI into the full Data Availability Statement, which is requested in the Additional Information section of the PLOS submission form. Then provide the URL passcode in the Attach Files section.

If you have any questions, please email us.

Accession numbers
All appropriate data sets, images, and information should be deposited in an appropriate public repository. See our list of recommended repositories.
Accession numbers (and version numbers, if appropriate) should be provided in the Data Availability Statement. Accession numbers or a citation to the DOI should also be provided when the data set is mentioned within the manuscript.
In some cases authors may not be able to obtain accession numbers of DOIs until the manuscript is accepted; in these cases, the authors must provide these numbers at acceptance. In all other cases, these numbers must be provided at submission.
Identifiers
As much as possible, please provide accession numbers or identifiers for all entities such as genes, proteins, mutants, diseases, etc., for which there is an entry in a public database, for example:

- Ensembl
- Entrez Gene
- FlyBase
- InterPro
- Mouse Genome Database (MGD)
- Online Mendelian Inheritance in Man (OMIM)
- PubChem

Identifiers should be provided in parentheses after the entity on first use.

Small and macromolecule crystal data
Manuscripts reporting new and unpublished three-dimensional structures must include sufficient supporting data and detailed descriptions of the methodologies used to allow the reproduction and validation of the structures. All novel structures must have been deposited in a community endorsed database prior to submission (please see our list of recommended repositories).
Small molecule single crystal data
Authors reporting X-Ray crystallographic structures of small organic, metal-organic, and inorganic molecules must deposit their data with the Cambridge Crystallographic Data Centre (CCDC), the Inorganic Crystal Structure Database (ICSD), or similar community databases providing a recognized validation functionality. Authors are also required to include the relevant structure reference numbers within the main text (e.g. the CCDC ID number), as well as the crystallographic information files (.cif format) as Supplementary Information, along with the checkCIF validation reports that can be obtained via the International Union of Crystallography (IUCr).
Macromolecular structures
Authors reporting novel macromolecular structures must have deposited their data prior to submission with the Worldwide Protein Data Bank (wwPDB), the Biological Magnetic Resonance Data Bank (BMRB), the Electron Microscopy Data Bank (EMDB), or other community databases providing a recognized validation functionality. Authors must include the structure reference numbers within the main text and submit as Supplementary Information the official validation reports from these databases.

Striking image
You can upload a visually striking image alongside your submission, which we may use to showcase your article through PLOS' online channels. We choose the monthly issue image from the striking images submitted with articles scheduled for publication.
Submission Criteria

- Choose an image that represents the article in a striking and eye-catching way.
- It can be derived from a figure or supporting information file from the paper, and it may be a cropped portion of an image or the entire image.
- Alternatively, you can create or source an image, as long as it adheres to our CC BY license.
- High resolution: between 300-600 dpi
- Single panel
- Ideally avoid added details like text, scale bars, and arrows.

How to Submit

1. Submit your striking image to the submission system using the file type "Striking Image".
2. Upload a separate file with the corresponding caption.

If no striking image is uploaded, a member of the journal team will choose an appropriate image, which may be a figure from the submission or a separately sourced CC BY image.

Additional Information Requested at Submission

Financial Disclosure Statement

This information should describe sources of funding that have supported the work. If your manuscript is published, your statement will appear in the Funding section of the article.
Include your statement in the Financial Disclosure section of the submission form.
The statement should include:

- Specific grant numbers
- Initials of authors who received each award
- URLs to sponsors' websites

Also state whether any sponsors or funders (other than the named authors) played any role in:

- Study design
- Data collection and analysis
- Decision to publish
- Preparation of the manuscript

If they had no role in the research, include this sentence: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."
If the study was unfunded, include this sentence as the Financial Disclosure statement: "The author(s) received no specific funding for this work."

Competing Interests

The corresponding author is asked at submission to declare, on behalf of all authors, whether there are any financial, personal, or professional interests that could be construed to have influenced the work.
Any relevant competing interests of authors must be available to editors and reviewers during the review process and will be stated in published articles.

Related manuscripts

When submitting a manuscript, all authors are asked to indicate that they do not have a related or duplicate manuscript under consideration (or accepted) for publication elsewhere. If related work has been or will be submitted elsewhere or is in press elsewhere, then a copy must be uploaded with the article submitted to PLOS. Reviewers will be asked to comment on the overlap between related submissions.

Preprints

PLOS encourages authors to post preprints as a way to accelerate the dissemination of research and supports authors who wish to share their work early and receive feedback before formal peer review. Deposition of manuscripts with preprint servers does not impact consideration of the manuscript at any PLOS journal.
Authors posting on bioRxiv may concurrently submit directly to PLOS journals through bioRxiv's direct transfer to journal service.
Authors submitting manuscripts in the life sciences to *PLOS Neglected Tropical Diseases* may opt-in to post their work on bioRxiv during the *PLOS Neglected Tropical Diseases* initial submission process.

Reviewer and editor suggestions

We ask authors to suggest suitable editors and at least four potential reviewers when submitting their manuscript. Bear in mind any potential competing interests when making these suggestions. It is not appropriate to suggest recent collaborators or other researchers at your institution. See our policy on competing interests for more information.
Guidelines for Specific Study Types

Human and animal research

All research involving humans and animals must have been approved by the authors' institutional review board or equivalent committee(s), and that board must be named by the authors in the manuscript. For research involving human participants, informed consent must have been obtained (or the reason for lack of consent explained, e.g.

the data were analyzed anonymously) and all clinical investigation must have been conducted according to the principles expressed in the Declaration of Helsinki. It must be stated in the Methods section of the paper whether informed consent was written or oral. If informed consent was oral, it must be stated in the paper: (a) why written consent could not be obtained, (b) that the IRB approved the use of oral consent, and (c) how oral consent was documented.
Authors should be able to submit, upon request, a statement from the research ethics committee or institutional review board indicating approval of the research. We also encourage authors to submit a sample of a patient consent form, and may require submission on particular occasions.
All animal work must have been conducted according to relevant national and international guidelines. In accordance with the recommendations of the Weatherall report, *The use of non-human primates in research*, we specifically require authors to include details of animal welfare and steps taken to ameliorate suffering in all work involving non-human primates. The institution that approved the study must be named, and it must be stated in the paper that the study was conducted adhering to the institution's guidelines for animal husbandry.

Systematic reviews and meta-analyses
Submissions with systematic reviews and meta-analyses are considered research articles. Submit these manuscripts with the "Research Article" type in the submission system.
Reports of systematic reviews and meta-analyses must adhere to the PRISMA Statement or alternative guidelines appropriate to the study design, and include the completed checklist and flow diagram to accompany the main text. Authors must complete the appropriate reporting checklist not only with page references, but also with sufficient text excerpted from the manuscript to explain how they accomplished all applicable items.
Abstracts should follow PRISMA for Abstracts, using the PLOS abstract format. Authors must also state within the Methods section of their paper whether a protocol exists for their systematic review, and if so, provide a copy of the protocol as supporting information.
The journal supports the prospective registration of systematic reviews. Authors whose systematic review was prospectively registered (e.g., in a registry such as PROSPERO) should provide the registry number in their abstract. Registry details and protocols will be made available to editors and reviewers, and included with the paper if the report is ultimately published.

Diagnostic studies
Reports of studies of diagnostic accuracy must adhere to the STARD requirements or alternative guidelines appropriate to the study design (see the EQUATOR web site) and include a completed checklist as supporting information. Authors must complete the appropriate reporting checklist not only with page references, but also with sufficient text excerpted from the manuscript to explain how they addressed all applicable items.

Observational studies
For observational studies, including case control, cohort, and cross-sectional studies, authors must adhere to the STROBE Statement or alternative guidelines appropriate to the study design (see the EQUATOR web site) and include a completed checklist as supporting information. Authors must complete the appropriate reporting checklist not only with page references, but also with sufficient text excerpted from the manuscript to explain how they addressed all applicable items.
For observational studies, authors are required to clearly specify (a) What specific hypotheses the researchers intended to test, and the analytical methods by which they planned to test them; (b) What analyses they actually performed; and (c) When reported analyses differ from those that were planned, authors must provide transparent explanations for differences that affect the reliability of the study's results.
If a prospective analysis plan (from the study's funding proposal, IRB or other ethics committee submission, study protocol, or other planning document written before analyzing the data) was used in designing an observational study, authors must include the relevant prospectively written document with the manuscript submission for access by editors and reviewers and eventual publication alongside the accepted paper. If no prospectively written document exists, authors should explain how and when they determined the analyses being reported.

Microarray experiments
Reports of microarray experiments must conform to the MIAME guidelines, and the data from the experiments must be deposited in a publicly accessible database.
Other Article Types
If you are submitting content other than a research article, read the guidelines for other article types.